{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:06:08Z","timestamp":1790798768562,"version":"4.1.0"},"reference-count":794,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010146","name":"Alzheimer Research Initiative","doi-asserted-by":"publisher","award":["21043"],"award-info":[{"award-number":["21043"]}],"id":[{"id":"10.13039\/100010146","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARG-23-1141447"],"award-info":[{"award-number":["AARG-23-1141447"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024474","name":"Australian Farm Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024474","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["LA4465"],"award-info":[{"award-number":["LA4465"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["PO732"],"award-info":[{"award-number":["PO732"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pharmr.2025.100071","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:01:48Z","timestamp":1748458908000},"page":"100071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting the serotonergic system in the treatment of neurodegenerative diseases\u2014emerging therapies and unmet challenges"],"prefix":"10.1016","volume":"77","author":[{"given":"Alina","family":"Br\u00fcge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-5130","authenticated-orcid":false,"given":"Evgeni","family":"Ponimaskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-6382","authenticated-orcid":false,"given":"Josephine","family":"Labus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4306","key":"10.1016\/j.pharmr.2025.100071_bib1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/169800b0","article-title":"Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine","volume":"169","author":"Erspamer","year":"1952","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00391792","article-title":"Ricerche sul secreto delle cellule enterocromaffini","volume":"27","author":"Vialli","year":"1937","journal-title":"Z Zellforsch Mikrosk Anat"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.pharmr.2025.100071_bib4","first-page":"367","article-title":"Serotonin in mood and emotion","volume":"Vol 21","author":"Hensler","year":"2010"},{"key":"10.1016\/j.pharmr.2025.100071_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejphar.2014.10.031","article-title":"Serotonin: a never-ending story","volume":"753","author":"Olivier","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1749-6632.1990.tb16906.x","article-title":"Serotonin and nociception","volume":"600","author":"Richardson","year":"1990","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/smrv.2001.0174","article-title":"Serotonin and sleep","volume":"6","author":"Ursin","year":"2002","journal-title":"Sleep Med Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0165-3806(82)90095-5","article-title":"The time of genesis, embryonic origin and differentiation of the brain stem monoamine neurons in the rhesus monkey","volume":"256","author":"Levitt","year":"1982","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100071_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pneurobio.2016.03.007","article-title":"How serotonin receptors regulate morphogenic signalling in neurons","volume":"151","author":"Wirth","year":"2017","journal-title":"Prog Neurobiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib10","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10571-021-01064-9","article-title":"The roles of serotonin in neuropsychiatric disorders","volume":"42","author":"Pourhamzeh","year":"2022","journal-title":"Cell Mol Neurobiol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100071_bib11","doi-asserted-by":"crossref","first-page":"9240","DOI":"10.1021\/jm300953p","article-title":"Identification of multiple 5-HT4 partial agonist clinical candidates for the treatment of Alzheimer\u2019s disease","volume":"55","author":"Brodney","year":"2012","journal-title":"J Med Chem"},{"issue":"9916","key":"10.1016\/j.pharmr.2025.100071_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"Pt 2","key":"10.1016\/j.pharmr.2025.100071_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/brain\/aws274","article-title":"Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: a link to spasticity","volume":"136","author":"Dentel","year":"2013","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1749-6632.1957.tb40753.x","article-title":"A concept for a role of serotonin and norepinephrine as chemical mediators in the brain","volume":"66","author":"Brodie","year":"1957","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00337069","article-title":"Evidence for the existence of monoamine neurons in the central nervous system: III. The monoamine nerve terminal","volume":"65","author":"Fuxe","year":"1965","journal-title":"Z Zellforsch Mikrosk Anat"},{"key":"10.1016\/j.pharmr.2025.100071_bib16","first-page":"1","article-title":"Immunomodulatory effects mediated by serotonin","volume":"2015","author":"Arreola","year":"2015","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02454144","article-title":"Effect of intrathecal serotonin on nociception in rats: influence of the pain test used","volume":"113","author":"Bardin","year":"1997","journal-title":"Exp Brain Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0028-3908(84)90098-4","article-title":"Serotonin and appetite","volume":"23","author":"Blundell","year":"1984","journal-title":"Neuropharmacology"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100071_bib19","doi-asserted-by":"crossref","first-page":"13525","DOI":"10.1073\/pnas.2233056100","article-title":"Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function","volume":"100","author":"C\u00f4t\u00e9","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molmed.2004.03.007","article-title":"Recent advances in understanding serotonin regulation of cardiovascular function","volume":"10","author":"C\u00f4t\u00e9","year":"2004","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1073\/pnas.79.2.660","article-title":"Mechanism for shifting the phase of a circadian rhythm by serotonin: involvement of cAMP","volume":"79","author":"Eskin","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2025.100071_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2014.00306","article-title":"Cellular mechanisms of the 5-HT7 receptor-mediated signaling","volume":"8","author":"Guseva","year":"2014","journal-title":"Front Behav Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/jcp.24.3.250","article-title":"An assessment of platelet aggregation induced by 5-hydroxytryptamine: Part I after pre-incubation with 5-hydroxytryptamine and reserpine","volume":"24","author":"Hilton","year":"1971","journal-title":"J Clin Pathol"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100071_bib24","first-page":"2866","article-title":"Serotonin receptor 5-HT7 regulates morphology and migratory properties of dendritic cells","volume":"128","author":"Holst","year":"2015","journal-title":"J Cell Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib25","doi-asserted-by":"crossref","first-page":"R1260","DOI":"10.1152\/ajpregu.1998.274.5.R1260","article-title":"Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function","volume":"274","author":"Lin","year":"1998","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1160\/TH03-05-0330","article-title":"The influence of selective serotonin reuptake inhibitors on human platelet serotonin","volume":"91","author":"Maurer-Spurej","year":"2004","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.1964.tb00681.x","article-title":"Platelet clumping in vitro","volume":"10","author":"Mitchell","year":"1964","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/07853899909019259","article-title":"Serotonin and the regulation of mammalian circadian rhythmicity","volume":"31","author":"Morin","year":"1999","journal-title":"Ann Med"},{"issue":"2-5","key":"10.1016\/j.pharmr.2025.100071_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000158802","article-title":"Mechanisms involved in serotonin-induced vasodilatation","volume":"27","author":"Mylecharane","year":"1990","journal-title":"J Vasc Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jcp.17.3.275","article-title":"A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors","volume":"17","author":"O\u2019Brien","year":"1964","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-3565(25)05007-4","article-title":"The vascular action of natural serotonin, 5- and 7-hydroxytryptamine and tryptamine","volume":"105","author":"Page","year":"1952","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0893-133X(95)00026-A","article-title":"Serotonin and thermoregulation physiologic and pharmacologic aspects of control revealed by intravenous m-CPP in normal human subjects","volume":"13","author":"Schwartz","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00221-013-3818-4","article-title":"The role of serotonin in memory: interactions with neurotransmitters and downstream signaling","volume":"232","author":"Seyedabadi","year":"2014","journal-title":"Exp Brain Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib34","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cell.2009.06.051","article-title":"A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure","volume":"138","author":"Yadav","year":"2009","journal-title":"Cell"},{"issue":"4913","key":"10.1016\/j.pharmr.2025.100071_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/2001325a0","article-title":"A new concept of temperature regulation by amines in the hypothalamus","volume":"200","author":"Feldberg","year":"1963","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100071_bib36","first-page":"91","article-title":"The serotoninergic system and sleep-wakefulness regulation","volume":"Vol 116","author":"Adrien","year":"1995"},{"key":"10.1016\/j.pharmr.2025.100071_bib37","series-title":"5-Hydroxytryptamine and Related Indolealkylamines","first-page":"132","article-title":"Occurrence of indolealkylamines in nature","author":"Erspamer","year":"1966"},{"issue":"3680","key":"10.1016\/j.pharmr.2025.100071_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.149.3680.197","article-title":"Serotonin: synthesis and release from the myenteric plexus of the mouse intestine","volume":"149","author":"Gershon","year":"1965","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","article-title":"The serotonin signaling system: from basic understanding to drug development for functional GI disorders","volume":"132","author":"Gershon","year":"2007","journal-title":"Gastroenterology"},{"issue":"SUPPL 232","key":"10.1016\/j.pharmr.2025.100071_bib40","first-page":"1","article-title":"Evidence for the existence of monoamine neurons in the central nervous system I. Demonstration of monoamines in the cell bodies of brain stem neurons","author":"Dahlstroem","year":"1964","journal-title":"Acta Physiol Scand Suppl"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.1992.72.1.165","article-title":"Structure and function of the brain serotonin system","volume":"72","author":"Jacobs","year":"1992","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0021-9258(18)65440-7","article-title":"5-Hydroxytryptophan decarboxylase: preparation and properties","volume":"210","author":"Clark","year":"1954","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2885.2008.00944.x","article-title":"Serotonin: a review","volume":"31","author":"Mohammad-Zadeh","year":"2008","journal-title":"J Vet Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib44","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0021-9258(18)70190-7","article-title":"The metabolism of serotonin (5-hydroxytryptamine)","volume":"234","author":"McIsaac","year":"1959","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100071_bib45","first-page":"103","article-title":"Classification and signaling characteristics of 5-HT receptors","volume":"Vol 21","author":"Bockaert","year":"2010"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib46","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2982.2009.01275.x","article-title":"5-hydroxyindalpine, an agonist at the putative 5-HT receptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon","volume":"21","author":"Mitchell","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.pharmr.2025.100071_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108155","article-title":"Central 5-HT receptors and their function; present and future","volume":"177","author":"Sharp","year":"2020","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0014-2999(79)90506-5","article-title":"Serotonin release is modulated by presynaptic autoreceptors","volume":"57","author":"Cerrito","year":"1979","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1113\/jphysiol.1993.sp019819","article-title":"Whole-cell recordings of inwardly rectifying K+ currents activated by 5-HT1A receptors on dorsal raphe neurones of the adult rat","volume":"469","author":"Penington","year":"1993","journal-title":"J Physiol (Lond)"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib50","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/PL00005301","article-title":"Activation of recombinant h 5-HT1B and h 5-HT1D receptors stably expressed in C6 glioma cells produces increases in Ca2+-dependent K+ current","volume":"358","author":"Le Grand","year":"1998","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib51","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0896-6273(90)90201-P","article-title":"Serotonin receptor activation reduces calcium current in an acutely dissociated adult central neuron","volume":"4","author":"Penington","year":"1990","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1113\/jphysiol.1995.sp020758","article-title":"Inhibition of N- and P-type calcium currents and the after-hyperpolarization in rat motoneurones by serotonin","volume":"485","author":"Bayliss","year":"1995","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1469-7793.1998.103bz.x","article-title":"Differential inhibition of N and P\/Q Ca 2+ currents by 5-HT 1A and 5-HT 1D receptors in spinal neurons of Xenopus larvae","volume":"510","author":"Sun","year":"1998","journal-title":"J Physiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib54","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0028-3908(84)90017-0","article-title":"Selective 5ht-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex","volume":"23","author":"Conn","year":"1984","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/NMM:1:3:197","article-title":"5-HT2A receptor activation leads to increased BDNF mRNA expression in C6 glioma cells","volume":"1","author":"Meller","year":"2002","journal-title":"Neuromolecular Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0896-6273(00)81010-7","article-title":"Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism","volume":"20","author":"Tao","year":"1998","journal-title":"Neuron"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100071_bib57","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1523\/JNEUROSCI.22-16-06846.2002","article-title":"Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism","volume":"22","author":"Carr","year":"2002","journal-title":"J Neurosci"},{"issue":"6227","key":"10.1016\/j.pharmr.2025.100071_bib58","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/339706a0","article-title":"5-HT3 receptors are membrane ion channels","volume":"339","author":"Derkach","year":"1989","journal-title":"Nature"},{"issue":"5030","key":"10.1016\/j.pharmr.2025.100071_bib59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1126\/science.1718042","article-title":"Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel","volume":"254","author":"Maricq","year":"1991","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib61","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0022-3565(25)24797-8","article-title":"5-Hydroxytryptamine4-like receptors mediate the slow excitatory response to serotonin in the rat hippocampus","volume":"257","author":"Andrade","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(02)00113-1","article-title":"The 5-HT4 receptor-induced depolarization in rat hippocampal neurons is mediated by cAMP but is independent of Ih","volume":"324","author":"Chapin","year":"2002","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib63","doi-asserted-by":"crossref","first-page":"H2367","DOI":"10.1152\/ajpheart.01375.2006","article-title":"Serotonin increases L-type Ca 2+ current and SR Ca 2+ content through 5-HT 4 receptors in failing rat ventricular cardiomyocytes","volume":"293","author":"Birkeland","year":"2007","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib64","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","article-title":"Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors","volume":"32","author":"Bonsi","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-3565(24)29552-5","article-title":"A 5-HT(7) receptor-mediated depolarization in the anterodorsal thalamus. II. Involvement of the hyperpolarization-activated current I(h)","volume":"297","author":"Chapin","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib66","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1081\/ERC-120016981","article-title":"Involvement of T-type calcium channels in the mechanism of action of 5-HT in rat glomerulosa cells: a novel signaling pathway for the 5-HT7 receptor","volume":"28","author":"Lenglet","year":"2002","journal-title":"Endocr Res"},{"issue":"34","key":"10.1016\/j.pharmr.2025.100071_bib67","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1523\/JNEUROSCI.1790-05.2005","article-title":"5-HT7 receptor is coupled to G subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology","volume":"25","author":"Kvachnina","year":"2005","journal-title":"J Neurosci"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100071_bib68","doi-asserted-by":"crossref","first-page":"20812","DOI":"10.1074\/jbc.M112216200","article-title":"5-Hydroxytryptamine 4(a) receptor is coupled to the G alpha subunit of heterotrimeric G13 protein","volume":"277","author":"Ponimaskin","year":"2002","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib69","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1124\/mol.104.008748","article-title":"Palmitoylation of the 5-hydroxytryptamine4a receptor regulates receptor phosphorylation, desensitization, and \u03b2-arrestin-mediated endocytosis","volume":"67","author":"Ponimaskin","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s42003-020-0791-x","article-title":"Serotonin 5-HT4 receptor boosts functional maturation of dendritic spines via RhoA-dependent control of F-actin","volume":"3","author":"Schill","year":"2020","journal-title":"Commun Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib71","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/cn500326z","article-title":"5-HT 6 receptor: a new player controlling the development of neural circuits","volume":"6","author":"Dayer","year":"2015","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.pharmr.2025.100071_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101900","article-title":"Amelioration of Tau pathology and memory deficits by targeting 5-HT7 receptor","volume":"197","author":"Labus","year":"2021","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmr.2025.100071_bib73","first-page":"301","article-title":"Concepts and classification of neurodegenerative diseases","volume":"Vol 145","author":"Kovacs","year":"2018"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib74","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1073\/pnas.85.11.4051","article-title":"Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau","volume":"85","author":"Goedert","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6686","key":"10.1016\/j.pharmr.2025.100071_bib75","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2032-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib76","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5796","key":"10.1016\/j.pharmr.2025.100071_bib77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"issue":"6645","key":"10.1016\/j.pharmr.2025.100071_bib78","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"Suppl 2","key":"10.1016\/j.pharmr.2025.100071_bib79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-2011-110182","article-title":"Targeting oligomers in neurodegenerative disorders: lessons from \u03b1-synuclein, tau, and amyloid-\u03b2 peptide","volume":"24","author":"Gadad","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib80","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib81","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib82","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: translating genetic discoveries into therapies","volume":"24","author":"Ak\u00e7imen","year":"2023","journal-title":"Nat Rev Genet"},{"issue":"10291","key":"10.1016\/j.pharmr.2025.100071_bib83","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100071_bib84","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.3390\/jcm13144100","article-title":"Charting Alzheimer\u2019s disease and dementia: epidemiological insights, risk factors and prevention pathways","volume":"13","author":"Contador","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib85","first-page":"149","article-title":"Epidemiology of Alzheimer\u2019s disease: latest trends","volume":"70","author":"Dumurgier","year":"2020","journal-title":"Rev Prat"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib86","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib88","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib91","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00415-019-09652-y","article-title":"Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"267","author":"Xu","year":"2020","journal-title":"J Neurol"},{"issue":"Supplement 1","key":"10.1016\/j.pharmr.2025.100071_bib92","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.wad.0000183086.99691.91","article-title":"Clinical features of frontotemporal dementia","volume":"19","author":"Boxer","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.pharmr.2025.100071_bib93","first-page":"207","article-title":"Clinical symptoms in Alzheimer\u2019s disease","volume":"Vol 89","author":"L\u00f3pez","year":"2008"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/14737175.2014.877842","article-title":"The pathomechanisms underlying Parkinson\u2019s disease","volume":"14","author":"Jellinger","year":"2014","journal-title":"Expert Rev Neurother"},{"issue":"9996","key":"10.1016\/j.pharmr.2025.100071_bib95","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"9769","key":"10.1016\/j.pharmr.2025.100071_bib96","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib97","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-022-00533-z","article-title":"Tauopathies: new perspectives and challenges","volume":"17","author":"Zhang","year":"2022","journal-title":"Mol Neurodegener"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib98","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib99","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","article-title":"TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"351","author":"Arai","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"6125","key":"10.1016\/j.pharmr.2025.100071_bib100","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1126\/science.1232927","article-title":"The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS","volume":"339","author":"Mori","year":"2013","journal-title":"Science"},{"issue":"5918","key":"10.1016\/j.pharmr.2025.100071_bib101","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib102","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1006\/nbdi.2001.0443","article-title":"Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues","volume":"8","author":"Watanabe","year":"2001","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib103","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archneur.55.3.294","article-title":"The genetics of Alzheimer disease: current status and future prospects","volume":"55","author":"Blacker","year":"1998","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib104","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11910-016-0707-9","article-title":"Genetics of frontotemporal dementia","volume":"16","author":"Olszewska","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WCO.0000000000001167","article-title":"Parkinson\u2019s disease \u2013 genetic cause","volume":"36","author":"Cherian","year":"2023","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib106","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","article-title":"Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100071_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411732","article-title":"Frontotemporal dementia, where do we stand? A narrative review","volume":"24","author":"Antonioni","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib108","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3934\/Neuroscience.2021005","article-title":"The biological pathways of Alzheimer disease: a review","volume":"8","author":"Calabr\u00f2","year":"2021","journal-title":"AIMS Neurosci"},{"key":"10.1016\/j.pharmr.2025.100071_bib109","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainresbull.2023.01.008","article-title":"Cell therapy in ALS: an update on preclinical and clinical studies","volume":"194","author":"Sironi","year":"2023","journal-title":"Brain Res Bull"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib115","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol Sin"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100071_bib116","doi-asserted-by":"crossref","first-page":"10153","DOI":"10.1074\/jbc.M116.743070","article-title":"Amyloid \u03b2 production is regulated by \u03b22-adrenergic signaling-mediated post-translational modifications of the ryanodine receptor","volume":"292","author":"Bussiere","year":"2017","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib117","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0014-5793(99)01028-5","article-title":"\u03b2-Amyloid fragment 25\u201335 selectively decreases complex IV activity in isolated mitochondria","volume":"457","author":"Canevari","year":"1999","journal-title":"FEBS Lett"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib118","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/acschemneuro.0c00811","article-title":"A\u03b2 oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors","volume":"12","author":"Fani","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.expneurol.2007.10.008","article-title":"Amyloid beta peptides and glutamatergic synaptic dysregulation","volume":"210","author":"Parameshwaran","year":"2008","journal-title":"Exp Neurol"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jneuroim.2004.01.005","article-title":"Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-\u03b2 onto the hippocampus in vivo","volume":"150","author":"Rosales-Corral","year":"2004","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib121","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1096\/fj.10-156661","article-title":"Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity","volume":"24","author":"Wang","year":"2010","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0896-6273(93)90279-Z","article-title":"Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding","volume":"11","author":"Biernat","year":"1993","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib123","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/0896-6273(93)90057-X","article-title":"Abnormal tau phosphorylation at Ser396 in Alzheimer\u2019s disease recapitulates development and contributes to reduced microtubule binding","volume":"10","author":"Bramblett","year":"1993","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib124","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1091\/mbc.3.10.1141","article-title":"Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau","volume":"3","author":"Drechsel","year":"1992","journal-title":"Mol Biol Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib125","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1083\/jcb.200605187","article-title":"Tau-dependent microtubule disassembly initiated by prefibrillar \u03b2-amyloid","volume":"175","author":"King","year":"2006","journal-title":"J Cell Biol"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100071_bib126","doi-asserted-by":"crossref","first-page":"7679","DOI":"10.1074\/jbc.270.13.7679","article-title":"Microtubule-associated protein\/microtubule affinity-regulating kinase (p110mark)","volume":"270","author":"Meyer","year":"1995","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100071_bib127","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.92.18.8463","article-title":"Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments","volume":"92","author":"Schweers","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib128","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1471-4159.1993.tb03642.x","article-title":"\u03c4 in paired helical filaments is functionally distinct from fetal \u03c4: assembly incompetence of paired helical filament-\u03c4","volume":"61","author":"Yoshida","year":"1993","journal-title":"J Neurochem"},{"issue":"5866","key":"10.1016\/j.pharmr.2025.100071_bib129","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.1152993","article-title":"Differential regulation of dynein and kinesin motor proteins by tau","volume":"319","author":"Dixit","year":"2008","journal-title":"Science"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100071_bib130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbadis.2004.07.002","article-title":"Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death","volume":"1739","author":"Feinstein","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib131","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib132","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000115115.98960.37","article-title":"Early A\u03b2 accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain","volume":"62","author":"Ingelsson","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmr.2025.100071_bib133","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.conb.2018.04.027","article-title":"Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease","volume":"51","author":"Tracy","year":"2018","journal-title":"Curr Opin Neurobiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib134","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib135","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1093\/brain\/awz313","article-title":"RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy","volume":"142","author":"Chen","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib136","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/hmg\/ddt498","article-title":"TDP-43 Phosphorylation by casein kinase I\u03b5 promotes oligomerization and enhances toxicity in vivo","volume":"23","author":"Choksi","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004803","article-title":"The tau tubulin kinases TTBK1\/2 promote accumulation of pathological TDP-43","volume":"10","author":"Liachko","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pharmr.2025.100071_bib138","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.nbd.2014.12.010","article-title":"TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca2+ signaling in motor neurons","volume":"75","author":"Mutihac","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib139","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bpa.12680","article-title":"Dysregulation of TDP-43 intracellular localization and early onset ALS are associated with a TARDBP S375G variant","volume":"29","author":"Newell","year":"2019","journal-title":"Brain Pathol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib140","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1074\/jbc.M115.695379","article-title":"Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1\u03b4 triggers mislocalization and accumulation of TDP-43","volume":"291","author":"Nonaka","year":"2016","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100071_bib141","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/cells11152398","article-title":"Suppression of linear ubiquitination ameliorates cytoplasmic aggregation of truncated TDP-43","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100071_bib142","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.febslet.2008.05.024","article-title":"A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro","volume":"582","author":"Winton","year":"2008","journal-title":"FEBS Lett"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib143","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nn.2779","article-title":"Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43","volume":"14","author":"Polymenidou","year":"2011","journal-title":"Nat Neurosci"},{"issue":"6248","key":"10.1016\/j.pharmr.2025.100071_bib144","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.aab0983","article-title":"TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD","volume":"349","author":"Ling","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1523\/JNEUROSCI.4988-09.2010","article-title":"Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis","volume":"30","author":"Barmada","year":"2010","journal-title":"J Neurosci"},{"issue":"31","key":"10.1016\/j.pharmr.2025.100071_bib146","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1038\/sj.onc.1203048","article-title":"Human POMp75 is identified as the pro-oncoprotein TLS\/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation","volume":"18","author":"Bertrand","year":"1999","journal-title":"Oncogene"},{"issue":"48","key":"10.1016\/j.pharmr.2025.100071_bib147","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.274.48.34337","article-title":"Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS\/FUS and is able to promote D-loop formation","volume":"274","author":"Baechtold","year":"1999","journal-title":"J Biol Chem"},{"issue":"43","key":"10.1016\/j.pharmr.2025.100071_bib148","doi-asserted-by":"crossref","first-page":"27761","DOI":"10.1074\/jbc.273.43.27761","article-title":"Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing","volume":"273","author":"Yang","year":"1998","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100071_bib149","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1242\/jcs.110.15.1741","article-title":"TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling","volume":"110","author":"Zinszner","year":"1997","journal-title":"J Cell Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib150","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using \u03b1-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib151","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jnen\/62.4.363","article-title":"Regional distribution of \u03b1-synuclein pathology in unimpaired aging and Alzheimer disease","volume":"62","author":"Parkkinen","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmr.2025.100071_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog Neurobiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib153","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12974-022-02565-0","article-title":"Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer\u2019s disease","volume":"19","author":"Singh","year":"2022","journal-title":"J Neuroinflamm"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib154","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0197-4580(84)90009-5","article-title":"A preliminary study of free amino acids in the postmorten temporal cortex from Alzheimer-type dementia patients","volume":"5","author":"Arai","year":"1984","journal-title":"Neurobiol Aging"},{"issue":"8223","key":"10.1016\/j.pharmr.2025.100071_bib155","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(81)92657-X","article-title":"Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia","volume":"317","author":"Bondareff","year":"1981","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib156","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cne.902870308","article-title":"Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson\u2019s disease with and without dementia and depression","volume":"287","author":"Chan-Palay","year":"1989","journal-title":"J Comp Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib157","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3940(88)90192-9","article-title":"Presynaptic and postsynaptic glutamatergic function in Alzheimer\u2019s disease","volume":"86","author":"Cowburn","year":"1988","journal-title":"Neurosci Lett"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib158","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0304-3940(87)90699-9","article-title":"Sodium dependent d-[3H]aspartate binding in cerebral cortex in patients with Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"79","author":"Cross","year":"1987","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib159","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ana.410200510","article-title":"A postmortem study of amino acid neurotransmitters in Alzheimer\u2019s disease","volume":"20","author":"Ellison","year":"1986","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib160","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s10072-013-1289-9","article-title":"Alzheimer\u2019s disease: amino acid levels and brain metabolic status","volume":"34","author":"Gueli","year":"2013","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib161","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/j.1471-4159.1989.tb09242.x","article-title":"Adrenergic receptors in aging and Alzheimer\u2019s disease: increased beta 2-receptors in prefrontal cortex and hippocampus","volume":"53","author":"Kalaria","year":"1989","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib162","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0022-510X(88)90020-2","article-title":"Studies on neurotransmitter markers of the basal ganglia in Pick\u2019s disease, with special reference to dopamine reduction","volume":"83","author":"Kanazawa","year":"1988","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib163","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-017-0411-2","article-title":"Locus coeruleus cellular and molecular pathology during the progression of Alzheimer\u2019s disease","volume":"5","author":"Kelly","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib164","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/jnc.14325","article-title":"GABAA receptor subunit expression changes in the human Alzheimer\u2019s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus","volume":"145","author":"Kwakowsky","year":"2018","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib165","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1471-4159.1988.tb02983.x","article-title":"Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer\u2019s disease","volume":"50","author":"Procter","year":"1988","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib166","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1212\/WNL.58.10.1489","article-title":"Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia","volume":"58","author":"Rinne","year":"2002","journal-title":"Neurology"},{"issue":"6422","key":"10.1016\/j.pharmr.2025.100071_bib167","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/bmj.288.6422.961","article-title":"Neurochemical characteristics of early and late onset types of Alzheimer\u2019s disease","volume":"288","author":"Rossor","year":"1984","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib168","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/brain\/105.2.313","article-title":"A post-mortem study of the cholinergic and GABA systems in senile dementia","volume":"105","author":"Rossor","year":"1982","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib169","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ana.410190307","article-title":"Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type","volume":"19","author":"Sasaki","year":"1986","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002100000346","article-title":"Differences between GABA levels in Alzheimer\u2019s disease and Down syndrome with Alzheimer-like neuropathology","volume":"363","author":"Seidl","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib171","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF01245715","article-title":"Loss of cortical GABA uptake sites in Alzheimer\u2019s disease","volume":"71","author":"Simpson","year":"1988","journal-title":"J Neural Transmission"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib172","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0197-4580(98)00086-4","article-title":"Decreased monoamine metabolites in frontotemporal dementia and Alzheimer\u2019s disease","volume":"19","author":"Sj\u00f6gren","year":"1998","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib173","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0404.1981.tb04392.x","article-title":"Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type","volume":"64","author":"Soininen","year":"2009","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib174","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer\u2019s disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib175","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/archneur.1984.04210080010005","article-title":"\u03b3-Aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer\u2019s type","volume":"41","author":"Zimmer","year":"1984","journal-title":"Arch Neurol"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100071_bib176","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1097\/00001756-199511270-00033","article-title":"Epibatidine and ABT 418 reveal selective losses of \u03b14\u03b22 nicotinic receptors in Alzheimer brains","volume":"6","author":"Warpman","year":"1995","journal-title":"NeuroReport"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib177","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0006-3223(00)01125-2","article-title":"Nicotinic receptor abnormalities of Alzheimer\u2019s disease: therapeutic implications","volume":"49","author":"Nordberg","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib178","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0169-328X(00)00031-0","article-title":"Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients","volume":"76","author":"Burghaus","year":"2000","journal-title":"Mol Brain Res"},{"issue":"8000","key":"10.1016\/j.pharmr.2025.100071_bib179","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer\u2019s disease","volume":"308","author":"Davies","year":"1976","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib180","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/jnnp.74.7.965","article-title":"Alterations of muscarinic acetylcholine receptors in atypical Pick\u2019s disease without Pick bodies","volume":"74","author":"Odawara","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib181","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/alz.12794","article-title":"Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer\u2019s disease neuropathological changes","volume":"19","author":"Schaeverbeke","year":"2023","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib182","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0197-4580(92)90073-7","article-title":"Cell loss in the nucleus raphes dorsalis in Alzheimer\u2019s disease","volume":"13","author":"Aletrino","year":"1992","journal-title":"Neurobiol Aging"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib183","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/BF00227741","article-title":"Brain stem serotonin-synthesizing neurons in Alzheimer\u2019s disease: a clinicopathological correlation","volume":"84","author":"Halliday","year":"1992","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib184","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/jnnp.46.1.96","article-title":"Serotonin nerve cells in Alzheimer\u2019s disease","volume":"46","author":"Mann","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ana.410170608","article-title":"Nucleus raphe dorsalis in Alzheimer\u2019s disease: neurofibrillary tangles and loss of large neurons","volume":"17","author":"Yamamoto","year":"1985","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib186","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ana.410240210","article-title":"The neuropathology of aminergic nuclei in Alzheimer\u2019s disease","volume":"24","author":"Zweig","year":"1988","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib187","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2990.2000.00254.x","article-title":"Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer\u2019s disease prospectively assessed for behavioural changes","volume":"26","author":"Chen","year":"2000","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib188","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1176\/appi.ajp.161.6.1096","article-title":"Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer\u2019s disease with and without depression","volume":"161","author":"Hendricksen","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib189","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00001756-200301200-00014","article-title":"Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders","volume":"14","author":"Kovacs","year":"2003","journal-title":"NeuroReport"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib190","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","article-title":"Serotonin 1A receptors in the living brain of Alzheimer\u2019s disease patients","volume":"103","author":"Kepe","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib191","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1471-4159.1983.tb11838.x","article-title":"Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer\u2019s disease","volume":"41","author":"Bowen","year":"1983","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib192","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.410220207","article-title":"Aminergic systems in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"22","author":"D\u2019Amato","year":"1987","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib193","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0006-8993(87)90492-6","article-title":"5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain","volume":"425","author":"Marcusson","year":"1987","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib194","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.neurobiolaging.2010.03.023","article-title":"Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer\u2019s disease: a combined [11C]DASB and [18F]altanserin-PET study","volume":"33","author":"Marner","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmr.2025.100071_bib195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nbd.2017.05.007","article-title":"Molecular imaging of serotonin degeneration in mild cognitive impairment","volume":"105","author":"Smith","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"51","key":"10.1016\/j.pharmr.2025.100071_bib196","doi-asserted-by":"crossref","first-page":"13805","DOI":"10.1523\/JNEUROSCI.4218-08.2008","article-title":"Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer\u2019s disease","volume":"28","author":"Liu","year":"2008","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib197","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cne.21985","article-title":"\u03b2-amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog","volume":"513","author":"Bernedo","year":"2009","journal-title":"J Comp Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib198","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1460-9568.2010.07274.x","article-title":"Serotonin fibre sprouting and increase in serotonin transporter immunoreactivity in the CA1 area of hippocampus in a triple transgenic mouse model of Alzheimer\u2019s disease","volume":"32","author":"Noristani","year":"2010","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib199","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1192\/bjp.135.3.216","article-title":"Changes in the brain catecholamines in patients with dementia of Alzheimer type","volume":"135","author":"Adolfsson","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib200","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1471-4159.1984.tb00913.x","article-title":"Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia","volume":"43","author":"Aral","year":"1984","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib201","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1006\/nbdi.2001.0398","article-title":"\u03b2-Amyloid(1-42)-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex","volume":"8","author":"Harkany","year":"2001","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib202","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.nbd.2004.04.010","article-title":"Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1","volume":"16","author":"Szapacs","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib203","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","article-title":"Cholinergic\u2013serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer\u2019s disease","volume":"43","author":"Garcia-Alloza","year":"2005","journal-title":"Neuropsychologia"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JAD-190577","article-title":"Neurotransmitter imbalance in the brain and Alzheimer\u2019s disease pathology","volume":"72","author":"Snowden","year":"2019","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3940(92)90322-X","article-title":"Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia","volume":"141","author":"Tohgi","year":"1992","journal-title":"Neurosci Lett"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib206","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.pnpbp.2009.07.004","article-title":"Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer\u2019s disease","volume":"33","author":"Muck-Seler","year":"2009","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib207","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000066025","article-title":"Biological correlates of clinical subgroups of Alzheimer\u2019s disease","volume":"14","author":"Sj\u00f6gren","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib208","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00001756-200207020-00021","article-title":"Postmortem serotoninergic correlates of cognitive decline in Alzheimer\u2019s disease","volume":"13","author":"Lai","year":"2002","journal-title":"Neuroreport"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib209","doi-asserted-by":"crossref","DOI":"10.1007\/BF02312201","article-title":"Tyrosine hydroxylase, tryptophan hydroxylase, and the biopterin cofactor in the brains from patients with Alzheimer\u2019s disease","volume":"1","author":"Nagatsu","year":"1989","journal-title":"J Neural Transm Gen Sect"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib210","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/JGP.0b013e3180488325","article-title":"A positron emission tomography study of 5-hydroxytryptamine-1a receptors in alzheimer disease","volume":"15","author":"Lanct\u00f4t","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7-8","key":"10.1016\/j.pharmr.2025.100071_bib211","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22235","article-title":"Decreased 5-HT1A binding in mild Alzheimer\u2019s disease-a positron emission tomography study","volume":"76","author":"Mattsson","year":"2022","journal-title":"Synapse"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib212","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/01.wnl.0000271377.52421.4a","article-title":"Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment","volume":"69","author":"Truchot","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib213","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.neuroimage.2008.01.030","article-title":"A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer\u2019s disease","volume":"40","author":"Truchot","year":"2008","journal-title":"NeuroImage"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib214","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.npp.1300330","article-title":"Differential involvement of 5-HT1B\/1D and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer\u2019s disease","volume":"29","author":"Garcia-Alloza","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","article-title":"Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease","volume":"974","author":"Lai","year":"2003","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib216","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1176\/appi.ajp.160.2.334","article-title":"Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory","volume":"160","author":"Yasuno","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib217","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00213-006-0329-z","article-title":"Search for correlations between serotonin 5-HT1A receptor expression and cognitive functions\u2014a strategy in translational psychopharmacology","volume":"185","author":"Borg","year":"2006","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib218","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.3390\/biomedicines10123118","article-title":"Serotonin receptor gene polymorphisms are associated with cerebrospinal fluid, genetic, and neuropsychological biomarkers of Alzheimer\u2019s disease","volume":"10","author":"Babi\u0107 Leko","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib219","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0197-4580(02)00137-9","article-title":"Imaging of the 5-HT2A system: age-, gender-, and Alzheimer\u2019s disease-related findings","volume":"24","author":"Versijpt","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00213-004-2077-2","article-title":"Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer\u2019s disease","volume":"179","author":"Lai","year":"2005","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib221","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2202-7-36","article-title":"Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients","volume":"7","author":"Lorke","year":"2006","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib222","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/JAD-2009-1031","article-title":"Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T\/C) in Alzheimer\u2019s disease: a 3-year follow-up longitudinal study","volume":"17","author":"Angelucci","year":"2009","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib223","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/hmg\/7.9.1507","article-title":"5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer\u2019s disease","volume":"7","author":"Holmes","year":"1998","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib224","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.b.10068","article-title":"Depression in Alzheimer\u2019s disease: the effect of serotonin receptor gene variation","volume":"119B","author":"Holmes","year":"2003","journal-title":"Am J Med Genet B"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib225","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/gps.1109","article-title":"5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"19","author":"Lam","year":"2004","journal-title":"Int J Geriat Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib226","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0006-3223(01)01114-3","article-title":"Association between 5-HT2A receptor polymorphism and psychotic symptoms in Alzheimer\u2019s disease","volume":"50","author":"Nacmias","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib227","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neurobiolaging.2006.10.011","article-title":"Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer\u2019s disease","volume":"29","author":"Pritchard","year":"2008","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib228","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1476-5381.1995.tb13303.x","article-title":"5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases","volume":"114","author":"Reynolds","year":"1995","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib229","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/cn300095t","article-title":"5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10","volume":"4","author":"Cochet","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib230","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.67051882.x","article-title":"Increased activity-regulating and neuroprotective efficacy of \u03b1-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain","volume":"67","author":"Furukawa","year":"1996","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib231","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13041-019-0447-2","article-title":"The secreted APP ectodomain sAPP\u03b1, but not sAPP\u03b2, protects neurons against A\u03b2 oligomer-induced dendritic spine loss and increased tau phosphorylation","volume":"12","author":"Tackenberg","year":"2019","journal-title":"Mol Brain"},{"issue":"s1","key":"10.1016\/j.pharmr.2025.100071_bib232","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1471-4159.2011.07584.x","article-title":"Functions of A\u03b2, sAPP\u03b1 and sAPP\u03b2: similarities and differences","volume":"120","author":"Chasseigneaux","year":"2012","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib233","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0304-3940(99)00802-2","article-title":"Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer\u2019s disease","volume":"276","author":"Tsai","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmr.2025.100071_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105185","article-title":"5-HT7 receptors in Alzheimer\u2019s disease","volume":"150","author":"Solas","year":"2021","journal-title":"Neurochem Int"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/518720","article-title":"A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population","volume":"81","author":"Liu","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib236","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3233\/JAD-2010-100117","article-title":"Plaque deposition dependent decrease in 5-HT2A serotonin receptor in A\u03b2PPswe\/PS1dE9 amyloid overexpressing mice","volume":"20","author":"Holm","year":"2010","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.pharmr.2025.100071_bib237","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neulet.2015.03.064","article-title":"5-HT1B and other related serotonergic proteins are altered in APPswe mutation","volume":"594","author":"Tajeddinn","year":"2015","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib238","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112152","article-title":"Aberrant serotonergic signaling contributes to the hyperexcitability of CA1 pyramidal neurons in a mouse model of Alzheimer\u2019s disease","volume":"42","author":"Wang","year":"2023","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib239","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40478-023-01546-5","article-title":"Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimer\u2019s disease","volume":"11","author":"Khan","year":"2023","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib240","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s11011-023-01242-2","article-title":"Imbalance of multiple neurotransmitter pathways leading to depression-like behavior and cognitive dysfunction in the triple transgenic mouse model of Alzheimer disease","volume":"38","author":"Zhang","year":"2023","journal-title":"Metab Brain Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib241","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40035-024-00425-w","article-title":"Dorsal raphe nucleus\u2013hippocampus serotonergic circuit underlies the depressive and cognitive impairments in 5\u00d7FAD male mice","volume":"13","author":"Chen","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.pharmr.2025.100071_bib242","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2024.138013","article-title":"Serotonin-2B receptor (5-HT2BR) expression and binding in the brain of APPswe\/PS1dE9 transgenic mice and in Alzheimer\u2019s disease brain tissue","volume":"844","author":"Anzalone","year":"2025","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib243","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0304-3940(00)01544-5","article-title":"Promoter polymorphism of the 5-HT transporter and Alzheimer\u2019s disease","volume":"294","author":"Hu","year":"2000","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib244","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-007-0992-8","article-title":"Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy","volume":"196","author":"Bowen","year":"2008","journal-title":"Psychopharmacology"},{"issue":"3-4","key":"10.1016\/j.pharmr.2025.100071_bib245","first-page":"172","article-title":"Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy","volume":"4","author":"Francis","year":"1993","journal-title":"Dementia"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib246","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/archneur.1991.00530200032014","article-title":"Altered serotonergic and cholinergic synaptic markers in Pick\u2019s disease","volume":"48","author":"Sparks","year":"1991","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib247","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s004010000293","article-title":"Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation: immunocytochemical and quantitative study using a graph method","volume":"101","author":"Yang","year":"2001","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib248","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3233\/JAD-160320","article-title":"Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer\u2019s disease","volume":"53","author":"Vermeiren","year":"2016","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmr.2025.100071_bib249","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000051219","article-title":"Neurochemical features of frontotemporal dementia","volume":"10","author":"Procter","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib250","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ana.20365","article-title":"Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration","volume":"57","author":"Franceschi","year":"2005","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib251","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pscychresns.2007.07.003","article-title":"Serotonin-1A receptors in frontotemporal dementia compared with controls","volume":"156","author":"Lanct\u00f4t","year":"2007","journal-title":"Psychiatry Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib252","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2165\/00023210-199504030-00002","article-title":"Tacrine-induced hepatotoxicity: tolerability and management","volume":"4","author":"Balson","year":"1995","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmr.2025.100071_bib253","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7252882","article-title":"Tacrine derivatives in neurological disorders: focus on molecular mechanisms and neurotherapeutic potential","volume":"2022","author":"Mitra","year":"2022","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib254","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/157340808786733631","article-title":"Cholinesterases and cholinesterase inhibitors","volume":"4","author":"Stepankova","year":"2008","journal-title":"Curr Enzyme Inhib"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021954","article-title":"Rivastigmine lowers A\u03b2 and increases sAPP\u03b1 levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons","volume":"6","author":"Bailey","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharmr.2025.100071_bib256","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuro.2013.10.004","article-title":"Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo","volume":"40","author":"Kim","year":"2014","journal-title":"NeuroToxicology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib257","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.brainres.2005.04.014","article-title":"Protective effect of donepezil against A\u03b2(1-40) neurotoxicity in rat septal neurons","volume":"1047","author":"Kimura","year":"2005","journal-title":"Brain Res"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100071_bib258","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-2999(00)00093-5","article-title":"Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer\u2019s disease","volume":"393","author":"Maelicke","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib259","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2009.01.024","article-title":"Galantamine inhibits \u03b2-amyloid aggregation and cytotoxicity","volume":"280","author":"Matharu","year":"2009","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib260","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1460-9568.2009.06612.x","article-title":"Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons","volume":"29","author":"Melo","year":"2009","journal-title":"Eur J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib261","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3233\/JAD-2003-5602","article-title":"Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro","volume":"5","author":"Reid","year":"2004","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib262","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2025.100071_bib263","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-0404.2000.00310.x","article-title":"Galantamine is an allosterically potentiating ligand of the human \u03b14\/\u03b22 nAChR: galantamine is a nicotinic APL","volume":"102","author":"Samochocki","year":"2000","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib264","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(00)01100-8","article-title":"Nicotinic receptor\u2013mediated protection against \u03b2-amyloid neurotoxicity","volume":"49","author":"Shimohama","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"51","key":"10.1016\/j.pharmr.2025.100071_bib265","doi-asserted-by":"crossref","first-page":"40180","DOI":"10.1074\/jbc.M110.142356","article-title":"Galantamine-induced amyloid-\u03b2 clearance mediated via stimulation of microglial nicotinic acetylcholine receptors","volume":"285","author":"Takata","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib266","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00001756-200502080-00006","article-title":"Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer\u2019s disease","volume":"16","author":"Venneri","year":"2005","journal-title":"NeuroReport"},{"issue":"9427","key":"10.1016\/j.pharmr.2025.100071_bib267","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD2000): randomised double-blind trial","volume":"363","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib268","first-page":"557","article-title":"Efficacy and safety of cholinesterase inhibitors in Alzheimer\u2019s disease: a meta-analysis","volume":"169","author":"Lanct\u00f4t","year":"2003","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib269","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00228-005-0946-1","article-title":"A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"61","author":"Raschetti","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib271","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd1311","article-title":"Memantine hydrochloride","volume":"3","author":"Witt","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100071_bib272","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib273","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/j.1460-9568.2008.06498.x","article-title":"Memantine protects rat cortical cultured neurons against \u03b2-amyloid-induced toxicity by attenuating tau phosphorylation","volume":"28","author":"Song","year":"2008","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib274","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0","article-title":"Memantine in severe dementia: results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine)","volume":"14","author":"Winblad","year":"1999","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib276","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib277","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/00185787231185869","article-title":"Lecanemab","volume":"59","author":"Levien","year":"2024","journal-title":"Hosp Pharm"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100071_bib278","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"7618","key":"10.1016\/j.pharmr.2025.100071_bib279","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib280","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Therapy"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib281","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib282","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100071_bib283","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3389\/fphar.2019.01045","article-title":"Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): management of extrapyramidal side effects","volume":"10","author":"Ohno","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib284","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","article-title":"A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease","volume":"21","author":"Takeda","year":"2006","journal-title":"Int J Geriat Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib285","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000080966","article-title":"Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression","volume":"19","author":"Andin","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib286","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","article-title":"The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner","volume":"306","author":"Rammes","year":"2001","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib287","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"DeMattos","year":"2012","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib288","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib289","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmr.2025.100071_bib290","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/j.parkreldis.2015.10.564","article-title":"Long-term effectiveness of NUPLAZIDTM (pimavanserin) in PD psychosis: data from 2 open-label studies","volume":"22","author":"Mills","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib291","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib292","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib293","first-page":"285","article-title":"Substituting clozapine for olanzapine in psychiatrically stable Parkinson\u2019s disease patients: results of an open label pilot study","volume":"21","author":"Friedman","year":"1998","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib294","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/mds.10620","article-title":"Quetiapine improves psychotic symptoms and cognition in Parkinson\u2019s disease","volume":"19","author":"Juncos","year":"2004","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib295","doi-asserted-by":"crossref","first-page":"661","DOI":"10.33588\/rn.3907.2004328","article-title":"Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson\u2019s disease","volume":"39","author":"L\u00f3pez del Val","year":"2004","journal-title":"Rev Neurol"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100071_bib296","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100071_bib297","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","article-title":"Serotonin signaling is associated with lower amyloid-\u03b2 levels and plaques in transgenic mice and humans","volume":"108","author":"Cirrito","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib298","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/hmg\/ddab054","article-title":"Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer\u2019s disease","volume":"30","author":"Reddy","year":"2021","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib299","article-title":"Protective effects of SSRI, Citalopram in mutant APP and mutant Tau expressed dorsal raphe neurons in Alzheimer\u2019s disease","volume":"1870","author":"Sawant","year":"2024","journal-title":"Biochim Biophys Acta (BBA)"},{"issue":"236","key":"10.1016\/j.pharmr.2025.100071_bib300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008169","article-title":"An antidepressant decreases CSF A\u03b2 production in healthy individuals and in transgenic AD mice","volume":"6","author":"Sheline","year":"2014","journal-title":"Sci Transl Med"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100071_bib301","doi-asserted-by":"crossref","first-page":"e2666","DOI":"10.1212\/WNL.0000000000010733","article-title":"Effect of escitalopram on A\u03b2 levels and plaque load in an Alzheimer mouse model","volume":"95","author":"Cirrito","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib302","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46558-1","article-title":"Escitalopram ameliorates cognitive impairment in D-galactose-injected ovariectomized rats: modulation of JNK, GSK-3\u03b2, and ERK signalling pathways","volume":"9","author":"Ibrahim","year":"2019","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100071_bib303","doi-asserted-by":"crossref","first-page":"e2658","DOI":"10.1212\/WNL.0000000000010725","article-title":"Effect of escitalopram dose and treatment duration on CSF A\u03b2 levels in healthy older adults: a controlled clinical trial","volume":"95","author":"Sheline","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib304","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.expneurol.2007.01.037","article-title":"Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice","volume":"205","author":"Nelson","year":"2007","journal-title":"Exp Neurol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib305","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2174\/1567205011666140812114715","article-title":"Fluoxetine improves behavioral performance by suppressing the production of soluble \u03b2-amyloid in APP\/PS1 mice","volume":"11","author":"Wang","year":"2014","journal-title":"Curr Alzheimer\u2019s Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib306","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s00213-018-4973-x","article-title":"The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocin-induced memory deficits in male rats","volume":"235","author":"Afshar","year":"2018","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib307","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13286","article-title":"Antiallergic drug desloratadine as a selective antagonist of 5HT2A receptor ameliorates pathology of Alzheimer\u2019s disease model mice by improving microglial dysfunction","volume":"20","author":"Lu","year":"2021","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib308","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-8993(02)03153-0","article-title":"Effect of a 5-HT2C serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs","volume":"951","author":"Arjona","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100071_bib309","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2013.12.029","article-title":"The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer\u2019s model","volume":"1551","author":"Spilman","year":"2014","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100071_bib310","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neuropharm.2017.08.031","article-title":"Chronic treatments with a 5-HT 4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer\u2019s disease","volume":"126","author":"Baranger","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib311","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.expneurol.2006.07.021","article-title":"Activation of 5-HT4 receptors inhibits secretion of \u03b2-amyloid peptides and increases neuronal survival","volume":"203","author":"Cho","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmr.2025.100071_bib312","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2013.00096","article-title":"Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer\u2019s disease","volume":"5","author":"Giannoni","year":"2013","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib313","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JAD-2012-111235","article-title":"5-HT4 receptor stimulation leads to soluble A\u03b2PP\u03b1 production through MMP-9 upregulation","volume":"32","author":"Hashimoto","year":"2012","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib314","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13024-016-0112-5","article-title":"Redundant Gs-coupled serotonin receptors regulate amyloid-\u03b2 metabolism in vivo","volume":"11","author":"Fisher","year":"2016","journal-title":"Mol Neurodegener"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib315","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.neurobiolaging.2013.01.020","article-title":"Chronic 5-HT4 receptor activation decreases A\u03b2 production and deposition in hAPP\/PS1 mice","volume":"34","author":"Tesseur","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib316","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-143012","article-title":"Escitalopram ameliorates Tau hyperphosphorylation and spatial memory deficits induced by protein kinase A activation in Sprague Dawley rats","volume":"47","author":"Ren","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib317","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12031-015-0519-4","article-title":"Escitalopram ameliorates forskolin-induced tau hyperphosphorylation in HEK239\/tau441 cells","volume":"56","author":"Ren","year":"2015","journal-title":"J Mol Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib318","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-200401","article-title":"Escitalopram alleviates Alzheimer\u2019s disease-type tau pathologies in the aged P301L tau transgenic mice","volume":"77","author":"Wang","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib319","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.18632\/oncotarget.7798","article-title":"Escitalopram attenuates \u03b2-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt\/GSK-3\u03b2 pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmr.2025.100071_bib320","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108218","article-title":"The antidepressant drug; trazodone inhibits Tau amyloidogenesis: prospects for prophylaxis and treatment of AD","volume":"679","author":"Akbari","year":"2020","journal-title":"Archives of Biochem Biophys"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib321","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1002\/alz.13090","article-title":"Amisulpride as a potential disease-modifying drug in the treatment of tauopathies","volume":"19","author":"Jahreis","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib322","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1015131516649","article-title":"Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]","volume":"21","author":"Youdim","year":"2001","journal-title":"Cell Mol Neurobiol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib323","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","article-title":"A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing","volume":"20","author":"Yogev-Falach","year":"2006","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib324","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neuropharm.2007.06.016","article-title":"VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux","volume":"53","author":"Mohler","year":"2007","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib325","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjp.0707178","article-title":"5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL\/6j mice","volume":"150","author":"Cachard-Chastel","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib326","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbr.2007.10.008","article-title":"Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl\/6j mice","volume":"187","author":"Cachard-Chastel","year":"2008","journal-title":"Behav Brain Res"},{"issue":"48","key":"10.1016\/j.pharmr.2025.100071_bib327","doi-asserted-by":"crossref","first-page":"44881","DOI":"10.1074\/jbc.M109008200","article-title":"The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein","volume":"276","author":"Robert","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100071_bib328","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175625","article-title":"Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer\u2019s disease: behavioural, neurochemical and pharmacological profiling","volume":"947","author":"Nirogi","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib329","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.neurobiolaging.2015.05.009","article-title":"Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice","volume":"36","author":"Weinreb","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib330","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1749-6632.2001.tb03622.x","article-title":"Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs","volume":"939","author":"Weinstock","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmr.2025.100071_bib331","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jchemneu.2019.01.008","article-title":"Protective effects of 5-HT1A receptor antagonist and 5-HT2A receptor agonist on the biochemical and histological features in a rat model of Alzheimer\u2019s disease","volume":"96","author":"Afshar","year":"2019","journal-title":"J Chem Neuroanat"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100071_bib332","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2005.07.021","article-title":"Blockade of 5-HT3 receptor with MDL72222 and Y25130 reduces \u03b2-amyloid protein (25\u201335)-induced neurotoxicity in cultured rat cortical neurons","volume":"520","author":"Ju Yeon","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib333","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/eci.12141","article-title":"Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats","volume":"43","author":"Rahimian","year":"2013","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib334","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/hmg\/ddab091","article-title":"Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer\u2019s disease","volume":"30","author":"Reddy","year":"2021","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib335","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0278-5846(03)00053-8","article-title":"A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson\u2019s disease","volume":"27","author":"Weinstock","year":"2003","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmr.2025.100071_bib336","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146375","article-title":"5-HT6 receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801","volume":"1722","author":"Rychtyk","year":"2019","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100071_bib337","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00200","article-title":"5-HT6 receptor agonism facilitates emotional learning","volume":"6","author":"Pereira","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100071_bib338","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2014.00391","article-title":"5-HT7 receptor activation promotes an increase in TrkB receptor expression and phosphorylation","volume":"8","author":"Samarajeewa","year":"2014","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.pharmr.2025.100071_bib339","series-title":"Advances in Research on Neurodegeneration","first-page":"157","article-title":"TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer\u2019s disease","author":"Weinstock","year":"2000"},{"issue":"15_supplement","key":"10.1016\/j.pharmr.2025.100071_bib340","article-title":"Procognitive and neuroprotective effect of 5-HT7 agonist in an animal model by ICV amyloid-b injection (P1.1-005)","volume":"92","author":"Quintero-Villegas","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.pharmr.2025.100071_bib341","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainresbull.2017.10.004","article-title":"The effects of the 5-HT7 receptor on hippocampal long-term potentiation and apoptosis in a rat model of Alzheimer\u2019s disease","volume":"135","author":"Hashemi-Firouzi","year":"2017","journal-title":"Brain Res Bull"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib342","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/sj.npp.1301644","article-title":"The promnesic effect of G-protein-coupled 5-HT4 receptors activation is mediated by a potentiation of learning-induced spine growth in the mouse hippocampus","volume":"33","author":"Restivo","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib343","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-017-0304-4","article-title":"Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer\u2019s disease by regulating cilia function","volume":"9","author":"Hu","year":"2017","journal-title":"Alzheimers Res Therapy"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib344","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1124\/jpet.105.086363","article-title":"Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties","volume":"314","author":"Schechter","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib345","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/j.1471-4159.1992.tb10983.x","article-title":"5-Hydroxytryptamine3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release","volume":"58","author":"Maura","year":"1992","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib346","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/00001756-199406020-00018","article-title":"5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex","volume":"5","author":"Consolo","year":"1994","journal-title":"Neuroreport"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib347","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1460-9568.2006.05003.x","article-title":"Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release","volume":"24","author":"Marcos","year":"2006","journal-title":"Eur J Neurosci"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100071_bib348","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2006.09.049","article-title":"SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models","volume":"553","author":"Hirst","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib349","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/jm021085c","article-title":"Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist","volume":"46","author":"Riemer","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100071_bib350","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pbb.2013.01.019","article-title":"Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats","volume":"105","author":"M\u00f8rk","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib351","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1476-5381.1995.tb15020.x","article-title":"NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist","volume":"115","author":"Dijk","year":"1995","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib352","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0006-8993(96)00395-2","article-title":"Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus","volume":"728","author":"Matsuyama","year":"1996","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib353","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","article-title":"The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus","volume":"25","author":"Dawson","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib354","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bjp.0703288","article-title":"In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate","volume":"130","author":"Dawson","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib355","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.euroneuro.2006.06.009","article-title":"Effects of the novel 5-HT6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating","volume":"17","author":"Schreiber","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib356","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11011-016-9932-9","article-title":"HBK-14 and HBK-15 with antidepressant-like and\/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice","volume":"32","author":"Pytka","year":"2017","journal-title":"Metab Brain Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib357","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuroscience.2004.06.070","article-title":"Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer\u2019s disease","volume":"129","author":"Spencer","year":"2004","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib358","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0304-3940(95)12063-A","article-title":"Serotoninergic modulation of excitability in area CA1 of the in vitro rat hippocampus","volume":"199","author":"Siarey","year":"1995","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib359","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0033-3182(97)71461-0","article-title":"A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer\u2019s disease","volume":"38","author":"Taragano","year":"1997","journal-title":"Psychosomatics"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib360","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/nlme.1998.3886","article-title":"5HT antagonists attenuate MK801-impaired radial arm maze performance in rats","volume":"71","author":"Boast","year":"1999","journal-title":"Neurobiol Learn Mem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib361","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0028-3908(99)00038-6","article-title":"WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors","volume":"38","author":"Carli","year":"1999","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib362","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0028-3908(99)00179-3","article-title":"The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys","volume":"39","author":"Harder","year":"2000","journal-title":"Neuropharmacology"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100071_bib363","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2999(95)00310-H","article-title":"(S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine","volume":"283","author":"Carli","year":"1995","journal-title":"Eur J Pharmacol"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib364","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0006-8993(96)00678-6","article-title":"Blockade of 5-HT1A receptors compensates loss of hippocampal cholinergic neurotransmission involved in working memory of rats","volume":"736","author":"Ohno","year":"1996","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib365","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pbb.2010.02.008","article-title":"Acute lecozotan administration increases learning and memory in rats without affecting anxiety or behavioral depression","volume":"95","author":"Skirzewski","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib366","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.bjp.0702915","article-title":"S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine","volume":"128","author":"Carli","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib367","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/sj.bjp.0703567","article-title":"Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT(1A) receptors in the dorsal raphe","volume":"131","author":"Carli","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib368","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00213-004-2114-1","article-title":"Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys","volume":"179","author":"Terry","year":"2005","journal-title":"Psychopharmacology"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib369","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0166-4328(97)00055-7","article-title":"Effects of the 5-HT receptor antagonists GR127935 (5-HT1B\/1D) and MDL100907 (5-HT2A) in the consolidation of learning","volume":"89","author":"Meneses","year":"1997","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-012-2746-5","article-title":"Reduced activity at the 5-HT2C receptor enhances reversal learning by decreasing the influence of previously non-rewarded associations","volume":"224","author":"Nilsson","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib371","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbr.2004.06.024","article-title":"The effect of intrahippocampal injections of ritanserin (5HT antagonist) and granisetron (5HT antagonist) on learning as assessed in the spatial version of the water maze","volume":"157","author":"Naghdi","year":"2005","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib372","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF02249414","article-title":"Comparison of the effects of the 5-HT3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system","volume":"125","author":"Hodges","year":"1996","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib373","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0197-4580(96)00162-5","article-title":"The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys","volume":"18","author":"Arnsten","year":"1997","journal-title":"Neurobiol Aging"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib374","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0006-8993(97)00448-4","article-title":"Differential effects of 5-HT3 receptor antagonism on working memory failure due to deficiency of hippocampal cholinergic and glutamatergic transmission in rats","volume":"762","author":"Ohno","year":"1997","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib375","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0091-3057(90)90385-U","article-title":"The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates","volume":"35","author":"Barnes","year":"1990","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib376","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0091-3057(92)90449-P","article-title":"Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset","volume":"42","author":"Carey","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib377","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0166-4328(97)80988-6","article-title":"Dose-related impairment of spatial learning by intrahippocampal scopolamine: antagonism by ondansetron, a 5-HT3 receptor antagonist","volume":"82","author":"Carli","year":"1997","journal-title":"Behav Brain Res"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100071_bib378","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(96)00586-9","article-title":"Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task","volume":"311","author":"Pitsikas","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib379","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s11064-020-03110-2","article-title":"Tropisetron but not granisetron ameliorates spatial memory impairment induced by chronic cerebral hypoperfusion","volume":"45","author":"Divanbeigi","year":"2020","journal-title":"Neurochem Res"},{"issue":"4-5","key":"10.1016\/j.pharmr.2025.100071_bib380","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0028-3908(97)00055-5","article-title":"The effects of novel, selective 5-hydroxytryptamine (5-HT) 4 receptor ligands in rat spatial navigation","volume":"36","author":"Fontana","year":"1997","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib381","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbr.2012.02.012","article-title":"Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice","volume":"230","author":"Freret","year":"2012","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib382","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0278-5846(02)00351-2","article-title":"Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats","volume":"27","author":"Lamirault","year":"2003","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib383","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0028-3908(01)00123-X","article-title":"Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors","volume":"41","author":"Lamirault","year":"2001","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib384","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00210-003-0743-2","article-title":"BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse","volume":"367","author":"Lelong","year":"2003","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib385","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s002130050529","article-title":"Enhanced delayed matching performance in younger and older macaques administered the 5-HT 4 receptor agonist, RS 17017","volume":"135","author":"Terry","year":"1998","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib386","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0022-3565(24)37700-6","article-title":"Role of 5-HT4 receptors in the mouse passive avoidance test","volume":"286","author":"Galeotti","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"issue":"4-5","key":"10.1016\/j.pharmr.2025.100071_bib387","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0028-3908(96)00169-4","article-title":"5-HT 4 receptors improve social olfactory memory in the rat","volume":"36","author":"Letty","year":"1997","journal-title":"Neuropharmacology"},{"issue":"4-5","key":"10.1016\/j.pharmr.2025.100071_bib388","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0028-3908(97)00058-0","article-title":"BIMU1 increases associative memory in rats by activating 5-HT 4 receptors","volume":"36","author":"Marchetti-Gauthier","year":"1997","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib389","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.brainres.2006.08.108","article-title":"Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia","volume":"1121","author":"Micale","year":"2006","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib390","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/jpet.102.034249","article-title":"SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties","volume":"302","author":"Moser","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib391","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.npp.1300332","article-title":"The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats","volume":"29","author":"Foley","year":"2004","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib392","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjp.2008.281","article-title":"Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat","volume":"155","author":"Marcos","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib393","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1476-5381.2012.02022.x","article-title":"5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms","volume":"167","author":"Woods","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib394","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pbb.2005.05.005","article-title":"Oral administration of the 5-HT receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task","volume":"81","author":"Perez-Garc\u00eda","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib395","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.neuropharm.2012.06.034","article-title":"Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457","volume":"63","author":"Callaghan","year":"2012","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib396","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nlm.2011.06.015","article-title":"Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats","volume":"96","author":"De Bruin","year":"2011","journal-title":"Neurobiol Learn Mem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib397","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2004.03.012","article-title":"5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation\u2014an effect sensitive to NMDA receptor antagonism","volume":"47","author":"King","year":"2004","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib398","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-4328(00)00316-8","article-title":"Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation","volume":"118","author":"Meneses","year":"2001","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib399","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-003-1552-5","article-title":"Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790","volume":"170","author":"Woolley","year":"2003","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib400","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/sj.npp.1300777","article-title":"The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat","volume":"30","author":"Lieben","year":"2005","journal-title":"Neuro-psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib401","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbr.2007.12.020","article-title":"Effect of 5-HT7 antagonist SB-269970 in the modulation of working and reference memory in the rat","volume":"195","author":"Gasbarri","year":"2008","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib402","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib403","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-009-1618-0","article-title":"Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat","volume":"206","author":"McLean","year":"2009","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib404","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbr.2011.12.009","article-title":"Effects of the selective 5-HT7 receptor antagonist SB-269970 in animal models of psychosis and cognition","volume":"228","author":"Waters","year":"2012","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib405","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav Brain Res"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100071_bib406","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib407","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bmc.2015.11.041","article-title":"N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT7 receptor selectivity versus multireceptor profile","volume":"24","author":"Canale","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib408","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.euroneuro.2013.10.011","article-title":"Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation","volume":"24","author":"Jensen","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100071_bib409","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2008.08.026","article-title":"5-HT7 receptor stimulation by 8-OH-DPAT counteracts the impairing effect of 5-HT1A receptor stimulation on contextual learning in mice","volume":"596","author":"Eriksson","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib410","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbr.2005.04.014","article-title":"Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task","volume":"163","author":"Perez-Garc\u00eda","year":"2005","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib411","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0306-4522(02)00937-5","article-title":"Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task","volume":"119","author":"Buccafusco","year":"2003","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib412","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-2229-z","article-title":"Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic\u2013pituitary\u2013adrenal axis in male and female prenatally stressed rats","volume":"181","author":"Poltyrev","year":"2005","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib413","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1192\/bjp.157.6.894","article-title":"The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders a Nordic multicentre study","volume":"157","author":"Nyth","year":"1990","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib414","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients","volume":"159","author":"Pollock","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","article-title":"A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer\u2019s disease in outpatients treated with donepezil","volume":"19","author":"Finkel","year":"2004","journal-title":"Int J Geriat Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib416","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.60.7.737","article-title":"Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS","volume":"60","author":"Lyketsos","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib417","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00019442-200409000-00007","article-title":"Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer\u2019s disease study (DIADS)","volume":"12","author":"Munro","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib418","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JGP.0b013e31826ce4c5","article-title":"Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease","volume":"20","author":"Munro","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib419","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-6647","article-title":"EEG power spectral analysis reveals tandospirone improves anxiety symptoms in patients with Alzheimer\u2019s disease: a prospective cohort study","volume":"9","author":"Liao","year":"2021","journal-title":"Ann Transl Med"},{"issue":"02","key":"10.1016\/j.pharmr.2025.100071_bib420","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S1461145706007000","article-title":"A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia","volume":"10","author":"Sato","year":"2007","journal-title":"Int J Neuropsychopharm"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib421","first-page":"41","article-title":"Therapeutic effect of Tandospirone citrate in Alzheimer\u2019s disease with depression and anxiety disorder","volume":"12","author":"Yu","year":"2018","journal-title":"Chin J Geriatr"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib422","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.biopsych.2005.05.012","article-title":"5-HT7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern","volume":"58","author":"Hedlund","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100071_bib423","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejphar.2006.09.064","article-title":"Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats","volume":"553","author":"Weso\u0142owska","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100071_bib424","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.3390\/molecules26133828","article-title":"Design, sustainable synthesis and biological evaluation of a novel dual \u03b12A\/5-HT7 receptor antagonist with antidepressant-like properties","volume":"26","author":"Canale","year":"2021","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib425","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/archneur.1985.04210090008003","article-title":"Evaluation of zimeldine in Alzheimer\u2019s disease: cognitive and biochemical measures","volume":"42","author":"Cutler","year":"1985","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib426","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.2001.tb03656.x","article-title":"The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo","volume":"939","author":"Youdim","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib427","article-title":"Selegiline for Alzheimer\u2019s disease","author":"Birks","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib428","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0165-1781(95)02714-8","article-title":"l-Deprenyl and physostigmine for the treatment of Alzheimer\u2019s disease","volume":"58","author":"Marin","year":"1995","journal-title":"Psychiatry Res"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib429","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-8993(96)01131-6","article-title":"Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635","volume":"745","author":"Hall","year":"1997","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib430","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(85)90856-X","article-title":"Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors","volume":"346","author":"Pazos","year":"1985","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib431","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0306-4522(87)90326-5","article-title":"Serotonin receptors in the human brain\u2014III. Autoradiographic mapping of serotonin-1 receptors","volume":"21","author":"Pazos","year":"1987","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib432","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1146\/annurev.ne.16.030193.002555","article-title":"Neuroanatomy of memory","volume":"16","author":"Zola-Morgan","year":"1993","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib433","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0006-8993(03)03352-3","article-title":"Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex","volume":"989","author":"Czyrak","year":"2003","journal-title":"Brain Res"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib434","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0006-8993(95)01005-5","article-title":"Serotonin and 8-OH-DPAT reduce excitatory transmission in rat hippocampal area CA1 via reduction in presumed presynaptic Ca2+ entry","volume":"701","author":"Schmitz","year":"1995","journal-title":"Brain Res"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib435","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0006-8993(97)81700-3","article-title":"WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid","volume":"774","author":"Carli","year":"1997","journal-title":"Brain Res"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib436","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02806000","article-title":"The 5-HI1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset","volume":"127","author":"Harder","year":"1996","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib437","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.105.092262","article-title":"5-hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms","volume":"316","author":"Madjid","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib438","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.npp.1300024","article-title":"Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat","volume":"28","author":"Misane","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib439","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0006-8993(03)03091-9","article-title":"The 5-HT1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task","volume":"983","author":"Pitsikas","year":"2003","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib440","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1460-9568.1998.00034.x","article-title":"Stimulation of 5-HT1A receptors in the dorsal raphe reverses the impairment of spatial learning caused by intrahippocampal scopolamine in rats","volume":"10","author":"Carli","year":"1998","journal-title":"Eur J Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib441","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF02245055","article-title":"5-HT1A receptor agonists improve the performance of normal and scopolamine-impaired rats in an operant delayed matching to position task","volume":"116","author":"Cole","year":"1994","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib442","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neuropharm.2005.01.007","article-title":"Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat","volume":"48","author":"L\u00fcttgen","year":"2005","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib443","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0028-3908(88)90181-5","article-title":"Serotonin-2 receptor-mediated regulation of release of acetylcholine by minaprine in cholinergic nerve terminal of hippocampus of rat","volume":"27","author":"Muramatsu","year":"1988","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib444","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-3565(24)37472-5","article-title":"5-Hydroxytryptamine2 receptor facilitates GABAergic neurotransmission in rat hippocampus","volume":"285","author":"Shen","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2025.100071_bib445","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","article-title":"Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice","volume":"64","author":"Zhang","year":"2013","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib446","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ncb1007","article-title":"Crosstalk between Rap1 and Rac regulates secretion of sAPP\u03b1","volume":"5","author":"Maillet","year":"2003","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib447","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0028-3908(00)00038-1","article-title":"Differential modulation of the 5-HT4 receptor agonists and antagonist on rat learning and memory","volume":"39","author":"Marchetti-Gauthier","year":"2000","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib448","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.npp.1301503","article-title":"Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466","volume":"33","author":"Schechter","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib449","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neuropharm.2011.05.004","article-title":"Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission","volume":"61","author":"Tassone","year":"2011","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib450","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0026-895X(25)13616-X","article-title":"Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs","volume":"43","author":"Monsma","year":"1993","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib451","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/bbrc.1993.1619","article-title":"A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation","volume":"193","author":"Ruat","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib452","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.neuroscience.2009.07.061","article-title":"Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus","volume":"164","author":"West","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmr.2025.100071_bib453","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128275","article-title":"Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer\u2019s disease","volume":"49","author":"Kucwaj-Brysz","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib454","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/biom13020309","article-title":"Progress in investigational agents targeting serotonin-6 receptors for the treatment of brain disorders","volume":"13","author":"Nirogi","year":"2023","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib455","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.neuroscience.2004.01.014","article-title":"Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine7 receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with \u03b12 adrenergic receptors","volume":"124","author":"Bonaventure","year":"2004","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib456","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.bjp.0705576","article-title":"Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species","volume":"141","author":"Mart\u00edn-Cora","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib457","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib458","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","article-title":"Meta-analysis of early nonmotor features and risk factors for Parkinson disease","volume":"72","author":"Noyce","year":"2012","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib459","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"De Lau","year":"2006","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib460","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E","article-title":"Synucleins in synaptic plasticity and neurodegenerative disorders","volume":"58","author":"Clayton","year":"1999","journal-title":"J Neurosci Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib461","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167775","article-title":"The role of \u03b1-synuclein in SNARE-mediated synaptic vesicle fusion","volume":"435","author":"Yoo","year":"2023","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib462","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.pharmr.2025.100071_bib463","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchemneu.2016.06.001","article-title":"Alpha-synuclein modulates dopamine neurotransmission","volume":"83-84","author":"Butler","year":"2017","journal-title":"J Chem Neuroanat"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib464","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of \u03b1-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib465","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both \u03b1-synuclein mutations linked to early-onset Parkinson\u2019s disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"10.1016\/j.pharmr.2025.100071_bib466","doi-asserted-by":"crossref","first-page":"21856","DOI":"10.1074\/jbc.M114.553297","article-title":"The H50Q mutation enhances \u03b1-synuclein aggregation, secretion, and toxicity","volume":"289","author":"Khalaf","year":"2014","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib467","doi-asserted-by":"crossref","first-page":"10710","DOI":"10.1074\/jbc.M308434200","article-title":"Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes \u03b1-synuclein inclusions","volume":"279","author":"Sawada","year":"2004","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib468","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/cn3002027","article-title":"Structures of the E46K mutant-type \u03b1-synuclein protein and impact of E46K mutation on the structures of the wild-type \u03b1-synuclein protein","volume":"4","author":"Wise-Scira","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"28","key":"10.1016\/j.pharmr.2025.100071_bib469","doi-asserted-by":"crossref","first-page":"19509","DOI":"10.1074\/jbc.274.28.19509","article-title":"\u03b1-synuclein fibrillogenesis is nucleation-dependent","volume":"274","author":"Wood","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100071_bib470","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.690293","article-title":"Alpha-synuclein post-translational modifications: implications for pathogenesis of Lewy body disorders","volume":"13","author":"Manzanza","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib471","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/gerona\/glaa176","article-title":"Person-specific contributions of brain pathologies to progressive parkinsonism in older adults","volume":"76","author":"Buchman","year":"2021","journal-title":"J Gerontol A"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib472","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib473","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/NEN.0b013e31816362aa","article-title":"Striatal \u03b2-amyloid deposition in parkinson disease with dementia","volume":"67","author":"Kalaitzakis","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib474","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.parkreldis.2012.11.003","article-title":"TARDBP mutations in Parkinson\u2019s disease","volume":"19","author":"Rayaprolu","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib475","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.expneurol.2010.06.017","article-title":"Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia","volume":"225","author":"Wills","year":"2010","journal-title":"Exp Neurol"},{"issue":"7628","key":"10.1016\/j.pharmr.2025.100071_bib476","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature20414","article-title":"Defects in trafficking bridge Parkinson\u2019s disease pathology and genetics","volume":"539","author":"Abeliovich","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib477","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-6606-2-5","article-title":"Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo","volume":"2","author":"Cullen","year":"2009","journal-title":"Mol Brain"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib478","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100071_bib479","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1523\/JNEUROSCI.0984-06.2006","article-title":"Parkinson\u2019s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled","volume":"26","author":"Keeney","year":"2006","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib480","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.410360612","article-title":"Complex I, iron, and ferritin in Parkinson\u2019s disease substantia nigra","volume":"36","author":"Mann","year":"1994","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib481","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s11064-023-03904-0","article-title":"Mitochondrial dysfunction and Parkinson\u2019s disease: pathogenesis and therapeutic strategies","volume":"48","author":"Moradi Vastegani","year":"2023","journal-title":"Neurochem Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib482","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and \u03b1-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.pharmr.2025.100071_bib483","first-page":"553","article-title":"Synaptic dysfunction in Parkinson\u2019s disease","volume":"Vol 970","author":"Picconi","year":"2012"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib484","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-6606-1-17","article-title":"Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity","volume":"1","author":"Qiao","year":"2008","journal-title":"Mol Brain"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib485","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1172\/JCI61332","article-title":"Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT\/mTOR signaling","volume":"122","author":"Selvaraj","year":"2012","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib486","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0002-9440(10)65396-5","article-title":"Parkinson\u2019s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons","volume":"154","author":"Zhang","year":"1999","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib487","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0006-8993(76)90005-6","article-title":"Evidence for the existence of a raphe projection to the substantia nigra in rat","volume":"113","author":"Dray","year":"1976","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib488","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cne.902430307","article-title":"The organization of divergent axonal projections from the midbrain raphe nuclei in the rat","volume":"243","author":"Imai","year":"1986","journal-title":"J Comp Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib489","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.902990102","article-title":"Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey","volume":"299","author":"Lavoie","year":"1990","journal-title":"J Comp Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib490","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0304-3940(85)90566-X","article-title":"Immunohistochemical demonstration of serotonin nerve fibers in the subthalamic nucleus of the rat, cat and monkey","volume":"62","author":"Mori","year":"1985","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib491","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cne.901800302","article-title":"Serotonin neurons of the midbrain raphe: ascending projections","volume":"180","author":"Moore","year":"1978","journal-title":"J Comp Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib492","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cne.902890111","article-title":"Ultrastructural relationships of serotonin axon terminals in the cerebral cortex of the adult rat","volume":"289","author":"S\u00e9gu\u00e9la","year":"1989","journal-title":"J Comp Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib493","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib494","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","article-title":"The neuropathologic basis of different clinical subgroups of Parkinson\u2019s disease","volume":"50","author":"Paulus","year":"1991","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib495","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410270405","article-title":"Neuropathology of immunohistochemically identified brainstem neurons in Parkinson\u2019s disease","volume":"27","author":"Halliday","year":"1990","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib496","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","article-title":"Loss of brainstem serotonin- and substance P-containing neurons in Parkinson\u2019s disease","volume":"510","author":"Halliday","year":"1990","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib497","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson\u2019s disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib498","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"Tremor in Parkinson\u2019s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib499","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0022-510X(71)90178-X","article-title":"Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson\u2019s disease and their role in akinesia, rigidity, chorea, and tremor","volume":"14","author":"Fahn","year":"1971","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib500","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib501","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","article-title":"Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson\u2019s disease","volume":"275","author":"Scatton","year":"1983","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib502","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0006-8993(94)91761-2","article-title":"Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson\u2019s disease and normal subjects","volume":"639","author":"Shannak","year":"1994","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib503","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/WNL.47.3.718","article-title":"Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson\u2019s disease","volume":"47","author":"Wilson","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0304-3940(93)90111-W","article-title":"Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms","volume":"150","author":"Tohgi","year":"1993","journal-title":"Neurosci Lett"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib505","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0304-3940(93)90817-5","article-title":"Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson\u2019s disease, and their changes after L-dopa administration","volume":"159","author":"Tohgi","year":"1993","journal-title":"Neurosci Lett"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib506","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF01260420","article-title":"Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients","volume":"62","author":"Sawada","year":"1985","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib507","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1471-4159.2010.07123.x","article-title":"Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson\u2019s disease: TPH2 misfolding and 5HT deficits in PD","volume":"116","author":"Kuhn","year":"2011","journal-title":"J Neurochem"},{"issue":"12_part_2","key":"10.1016\/j.pharmr.2025.100071_bib508","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1212\/WNL.20.12_Part_2.36","article-title":"Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism","volume":"20","author":"Chase","year":"1970","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib509","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/jnnp.40.12.1136","article-title":"CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders","volume":"40","author":"Davidson","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib510","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1471-4159.1969.tb05984.x","article-title":"Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism","volume":"16","author":"Gottfries","year":"1969","journal-title":"J Neurochem"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100071_bib511","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/0024-3205(67)90193-2","article-title":"5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson\u2019s syndrome","volume":"6","author":"Johansson","year":"1967","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib512","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.34.5.642","article-title":"Altered serotonin metabolism in depressed patients with Parkinson\u2019s disease","volume":"34","author":"Mayeux","year":"1984","journal-title":"Neurology"},{"issue":"5153","key":"10.1016\/j.pharmr.2025.100071_bib513","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/219502a0","article-title":"Concentrations of 5-hydroxyindole-acetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson\u2019s disease","volume":"219","author":"Olsson","year":"1968","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib514","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.22.1.62","article-title":"Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson\u2019s disease","volume":"22","author":"Rinne","year":"1972","journal-title":"Neurology"},{"issue":"2-5","key":"10.1016\/j.pharmr.2025.100071_bib515","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000103680","article-title":"On the occurrence of homovanillic acid and 5-hydroxyindol-3-ylacetic acid in the ventricular C.S.F. of patients suffering from parkinsonism","volume":"29","author":"Guldberg","year":"1967","journal-title":"Stereotact Funct Neurosurg"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib516","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00561323","article-title":"Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism","volume":"7","author":"Granerus","year":"1974","journal-title":"Eur J Clin Pharmacol"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100071_bib517","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF01248932","article-title":"Variability among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesions","volume":"77","author":"Commins","year":"1989","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib518","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/exnr.1994.1039","article-title":"Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats","volume":"126","author":"Karstaedt","year":"1994","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib519","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1460-9568.2009.06806.x","article-title":"Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation","volume":"30","author":"Nayyar","year":"2009","journal-title":"Eur J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib520","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0006-8993(91)91444-6","article-title":"Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset","volume":"567","author":"P\u00e9rez-Ota\u00f1o","year":"1991","journal-title":"Brain Res"},{"issue":"5-6","key":"10.1016\/j.pharmr.2025.100071_bib521","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00008877-200609000-00011","article-title":"Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects","volume":"17","author":"Van Vliet","year":"2006","journal-title":"Behav Pharmacol"},{"issue":"25","key":"10.1016\/j.pharmr.2025.100071_bib522","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1523\/JNEUROSCI.1495-09.2009","article-title":"Nonmotor symptoms of Parkinson\u2019s disease revealed in an animal model with reduced monoamine storage capacity","volume":"29","author":"Taylor","year":"2009","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib523","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10571-010-9509-9","article-title":"The roles of striatal serotonin and l-amino-acid decarboxylase on L-DOPA-induced dyskinesia in a hemiparkinsonian rat model","volume":"30","author":"Gil","year":"2010","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib524","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0014-2999(76)90042-X","article-title":"Circling behavior in rats with 6-hydroxydopamine or electrolytic nigral lesions","volume":"37","author":"Iwamoto","year":"1976","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib525","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1523\/JNEUROSCI.5031-09.2010","article-title":"High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson\u2019s disease","volume":"30","author":"Navailles","year":"2010","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib526","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(03)00295-7","article-title":"Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation","volume":"343","author":"Maeda","year":"2003","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib527","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0006-8993(91)90553-8","article-title":"Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain","volume":"556","author":"Zhou","year":"1991","journal-title":"Brain Res"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib528","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0006-8993(90)90036-B","article-title":"Elevation of dopamine D2 but not D1 receptors in adult rat neostriatum after neonatal 6-hydroxydopamine denervation","volume":"536","author":"Dewar","year":"1990","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib529","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0361-9230(87)90092-X","article-title":"Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat","volume":"19","author":"Luthman","year":"1987","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib530","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0006-8993(84)90665-6","article-title":"Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats","volume":"291","author":"Stachowiak","year":"1984","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib531","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0091-3057(89)90328-6","article-title":"Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: an anatomical, biochemical and pharmacological study","volume":"34","author":"Towle","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib532","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/cne.902450209","article-title":"Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study","volume":"245","author":"Snyder","year":"1986","journal-title":"J Comp Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib533","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.jcbfm.9600599","article-title":"Spared caudal brainstem SERT binding in early Parkinson\u2019s disease","volume":"28","author":"Albin","year":"2008","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib534","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-007-0015-2","article-title":"Loss of thalamic serotonin transporters in early drug-na\u00efve Parkinson\u2019s disease patients is associated with tremor: an [123I]\u03b2-CIT SPECT study","volume":"115","author":"Caretti","year":"2008","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib535","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0306-4522(93)90240-G","article-title":"Serotoninergic terminal transporters are differentially affected in Parkinson\u2019s disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram","volume":"54","author":"Chinaglia","year":"1993","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib536","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","article-title":"Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease","volume":"14","author":"Guttman","year":"2007","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib537","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1531-8257(200101)16:1<124::AID-MDS1007>3.0.CO;2-R","article-title":"[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients","volume":"16","author":"Haapaniemi","year":"2001","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib538","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archneur.60.9.1223","article-title":"Positron emission tomography of striatal serotonin transporters in Parkinson disease","volume":"60","author":"Kerenyi","year":"2003","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib539","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.36.4.556","article-title":"Parkinson\u2019s disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen","volume":"36","author":"Raisman","year":"1986","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib540","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson\u2019s disease: an in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib541","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/mds.23179","article-title":"Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study","volume":"25","author":"Roselli","year":"2010","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib542","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1468-1331.2010.03274.x","article-title":"Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson\u2019s disease \u2013 a [123I]-ADAM SPECT study","volume":"18","author":"Beucke","year":"2011","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib543","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00415-010-5666-5","article-title":"Preserved serotonin transporter binding in de novo Parkinson\u2019s disease: negative correlation with the dopamine transporter","volume":"258","author":"Strecker","year":"2011","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib544","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","article-title":"Fatigue in Parkinson\u2019s disease is linked to striatal and limbic serotonergic dysfunction","volume":"133","author":"Pavese","year":"2010","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib545","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000008206","article-title":"The serotonin transporter gene and Parkinson\u2019s disease","volume":"44","author":"McCann","year":"2000","journal-title":"Eur Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib546","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.mp.4000849","article-title":"Allelic variation of serotonin transporter expression is associated with depression in Parkinson\u2019s disease","volume":"6","author":"M\u00f6ssner","year":"2001","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib547","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","article-title":"Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson\u2019s disease","volume":"27","author":"Ballanger","year":"2012","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib548","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1749-6632.1998.tb10229.x","article-title":"Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson\u2019s disease neocortex","volume":"861","author":"Chen","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib549","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib550","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.870030310","article-title":"Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson\u2019s disease and progressive supranuclear palsy","volume":"3","author":"Maloteaux","year":"1988","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib551","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib552","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0022-510X(93)90074-9","article-title":"Reduction in cortical 5-HT3 binding sites following a unilateral 6-hydroxydopamine lesion of the medial forebrain bundle in rats","volume":"115","author":"\u010ci\u010din-\u0160ain","year":"1993","journal-title":"J Neurol Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib553","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/j.1460-9568.1996.tb01553.x","article-title":"Lesion study of the distribution of serotonin 5-HT4 receptors in rat basal ganglia and hippocampus","volume":"8","author":"Compan","year":"1996","journal-title":"Eur J Neurosci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib554","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0306-4522(95)00314-9","article-title":"Localization of serotonin-4 receptors in the striatonigral pathway in rat brain","volume":"69","author":"Patel","year":"1995","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib555","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(93)90073-Q","article-title":"Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington\u2019s disease","volume":"242","author":"Steward","year":"1993","journal-title":"Eur J Pharmacol"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib556","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0166-4328(96)00106-4","article-title":"Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders","volume":"73","author":"Wong","year":"1995","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmr.2025.100071_bib557","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainres.2011.01.086","article-title":"The pyramidal neurons in the medial prefrontal cortex show decreased response to 5-hydroxytryptamine-3 receptor stimulation in a rodent model of Parkinson\u2019s disease","volume":"1384","author":"Zhang","year":"2011","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib558","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.parkreldis.2011.08.009","article-title":"Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson\u2019s disease","volume":"18","author":"Lee","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib559","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1212\/WNL.58.5.828","article-title":"Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson\u2019s disease","volume":"58","author":"Messina","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib560","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib561","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1590\/0004-282x20180140","article-title":"Apomorphine in the treatment of Parkinson\u2019s disease: a review","volume":"76","author":"Pessoa","year":"2018","journal-title":"Arq Neuro-Psiquiatr"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib562","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"issue":"S11","key":"10.1016\/j.pharmr.2025.100071_bib563","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib564","article-title":"Efficacy and safety of deep brain stimulation in the treatment of Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Bratsos","year":"2018","journal-title":"Cureus"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100071_bib565","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib566","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib567","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2165\/00003495-197102040-00002","article-title":"Levodopa: a review of its pharmacological properties and therapeutic uses with particular reference to parkinsonism","volume":"2","author":"Brogden","year":"1971","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib568","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1212\/WNL.20.12_Part_2.6","article-title":"Double-blind, placebo-controlled study of levodopa therapy in Parkinson\u2019s disease","volume":"20","author":"Muenter","year":"1970","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib569","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.23590","article-title":"Pardoprunox in early Parkinson\u2019s disease: results from 2 large, randomized double-blind trials","volume":"26","author":"Sampaio","year":"2011","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib570","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","article-title":"Rasagiline mesylate, a new Mao-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa","volume":"23","author":"Rabey","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib571","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/ijerph19010364","article-title":"Systematic review on Parkinson\u2019s disease medications, emphasizing on three recently approved drugs to control Parkinson\u2019s symptoms","volume":"19","author":"Sivanandy","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.pharmr.2025.100071_bib572","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2024.108189","article-title":"Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with Parkinson\u2019s disease: systematic review and network meta-analysis","volume":"239","author":"Wu","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.pharmr.2025.100071_bib573","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00702-024-02799-7","article-title":"Anticholinergic drugs for parkinsonism and other movement disorders","volume":"131","author":"LeWitt","year":"2024","journal-title":"J Neural Transm"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib574","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1212\/WNL.55.8.1216","article-title":"Paroxetine in Parkinson\u2019s disease: effects on motor and depressive symptoms","volume":"55","author":"Ceravolo","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pharmr.2025.100071_bib575","series-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects","article-title":"Animal models of Parkinson\u2019s disease","author":"Konnova","year":"2018"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib576","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/14734220601016080","article-title":"Rodent models of tremor","volume":"6","author":"Miwa","year":"2007","journal-title":"Cerebellum"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib577","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00165384","article-title":"The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons","volume":"347","author":"Arborelius","year":"1993","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib578","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0022-3565(24)35231-0","article-title":"R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum","volume":"291","author":"Ichikawa","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib579","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(25)22843-9","article-title":"Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo","volume":"271","author":"Prisco","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"47","key":"10.1016\/j.pharmr.2025.100071_bib580","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action","volume":"25","author":"D\u00edaz-Mataix","year":"2005","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib581","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1098-2396(199810)30:2<172::AID-SYN7>3.0.CO;2-9","article-title":"Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535","volume":"30","author":"Lejeune","year":"1998","journal-title":"Synapse"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib582","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjp.0703139","article-title":"Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex","volume":"129","author":"Sakaue","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib583","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0014-2999(94)90669-6","article-title":"Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists","volume":"264","author":"Gudelsky","year":"1994","journal-title":"Eur J Pharmacol"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100071_bib584","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/0024-3205(90)90484-9","article-title":"Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by microdialysis","volume":"47","author":"Nash","year":"1990","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib585","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-3565(25)09555-2","article-title":"Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra","volume":"273","author":"Yamamoto","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2025.100071_bib586","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fnsys.2011.00048","article-title":"The 5-HT2A receptor antagonist M100907 produces antiparkinsonian effects and decreases striatal glutamate","volume":"5","author":"Ansah","year":"2011","journal-title":"Front Syst Neurosci"},{"key":"10.1016\/j.pharmr.2025.100071_bib587","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.nbd.2013.08.003","article-title":"Targeting 5-HT1A receptors in astrocytes to protect dopaminergic neurons in parkinsonian models","volume":"59","author":"Miyazaki","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmr.2025.100071_bib588","series-title":"Advances in Research on Neurodegeneration","first-page":"171","article-title":"Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022","author":"Maruyama","year":"2000"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100071_bib589","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0047-6374(00)00144-5","article-title":"Mechanism underlying anti-apoptotic activity of a (\u2212)deprenyl-related propargylamine, rasagiline","volume":"116","author":"Maruyama","year":"2000","journal-title":"Mech Ageing Dev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib590","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1749-6632.2001.tb03641.x","article-title":"Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022","volume":"939","author":"Maruyama","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib591","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.1994.tb21806.x","article-title":"Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline)","volume":"738","author":"Wu","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib592","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2006.02.003","article-title":"5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson\u2019s disease","volume":"23","author":"Bezard","year":"2006","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib593","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1124\/jpet.104.076554","article-title":"Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors","volume":"312","author":"Lane","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib594","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0893-133X(00)00206-2","article-title":"Role of 5-HT2A and 5-HT2B\/2C receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors","volume":"24","author":"McMahon","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmr.2025.100071_bib595","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2014.00180","article-title":"Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinsons disease","volume":"6","author":"Krishna","year":"2014","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib596","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1476-5381.1996.tb15419.x","article-title":"Prevention by (+\/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol","volume":"118","author":"Andersen","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib597","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","article-title":"Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat","volume":"55","author":"Dupre","year":"2008","journal-title":"Neuropharmacology"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100071_bib598","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/0024-3205(90)90365-X","article-title":"The effect of serotonergic agents on haloperidol-induced catalepsy","volume":"47","author":"Hicks","year":"1990","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib599","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s002130050265","article-title":"8-OH-DPAT, a 5-HT 1A agonist and ritanserin, a 5-HT 2A\/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release","volume":"131","author":"Lucas","year":"1997","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib600","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-3565(25)38100-0","article-title":"Serotonergic involvement in haloperidol-induced catalepsy","volume":"265","author":"Neal-Beliveau","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib601","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.pnpbp.2008.04.005","article-title":"Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test","volume":"32","author":"Ohno","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib602","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.neuropharm.2008.06.005","article-title":"Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens","volume":"55","author":"Ohno","year":"2008","journal-title":"Neuropharmacology"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100071_bib603","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","article-title":"5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy","volume":"453","author":"Prinssen","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib604","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00213-002-1121-3","article-title":"Postsynaptic 5-HT1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat","volume":"163","author":"Mignon","year":"2002","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib605","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-006-0680-0","article-title":"Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson\u2019s disease","volume":"192","author":"Mignon","year":"2007","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib606","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1734-1140(10)70264-4","article-title":"Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rats","volume":"62","author":"Nayebi","year":"2010","journal-title":"Pharmacol Rep"},{"issue":"3-6","key":"10.1016\/j.pharmr.2025.100071_bib607","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1163\/1569391041501924","article-title":"Antiparkinsonian actions of a selective 5-HT 1A agonist, tandospirone, in rats","volume":"18","author":"Ishibashi","year":"2004","journal-title":"Biog Amines"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib608","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1254\/jphs.08313FP","article-title":"Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice","volume":"109","author":"Ohno","year":"2009","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib609","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.22948","article-title":"Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson\u2019s disease","volume":"25","author":"Bronzova","year":"2010","journal-title":"Mov Disord"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100071_bib610","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/mds.23249","article-title":"Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib611","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euroneuro.2010.03.001","article-title":"An in vivo pharmacological evaluation of pardoprunox (SLV308) \u2014 A novel combined dopamine D2\/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson\u2019s disease","volume":"20","author":"Jones","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib612","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/syn.20102","article-title":"3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy","volume":"55","author":"Lebsanft","year":"2005","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib613","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejphar.2005.04.020","article-title":"3,4-Methylenedioxymethamphetamine and naloxone in rat rotational behaviour and open field","volume":"516","author":"Lebsanft","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib614","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00702-003-0823-y","article-title":"Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?","volume":"110","author":"Lebsanft","year":"2003","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib615","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0304-3940(02)00823-6","article-title":"Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?","volume":"330","author":"Schmidt","year":"2002","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib616","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1124\/jpet.104.066365","article-title":"Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A\/2C agonism","volume":"310","author":"Bishop","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib617","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2010.03.013","article-title":"5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson\u2019s disease","volume":"59","author":"Ferguson","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmr.2025.100071_bib618","first-page":"277","article-title":"Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson\u2019s disease","volume":"29","author":"Henderson","year":"1992","journal-title":"Clin Exp Neurol"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100071_bib619","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.08.019","article-title":"Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors","volume":"60","author":"Ohno","year":"2011","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib620","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jphs.2015.03.004","article-title":"Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice","volume":"127","author":"Shimizu","year":"2015","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib621","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pnpbp.2012.04.008","article-title":"Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders","volume":"38","author":"Tatara","year":"2012","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib622","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1353-8020(02)00011-1","article-title":"Mirtazapine in parkinsonian tremor","volume":"9","author":"Gordon","year":"2002","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib623","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.53.5.1154-a","article-title":"Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias","volume":"53","author":"Pact","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib624","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/exnr.1998.6792","article-title":"Behavioral effects of 5-HT2CReceptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease","volume":"151","author":"Fox","year":"1998","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib625","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF01259344","article-title":"Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism","volume":"64","author":"Baas","year":"1985","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib626","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00313593","article-title":"Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson\u2019s disease","volume":"230","author":"Biesemeyer","year":"1983","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib627","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/jnnp.49.4.390","article-title":"Mesulergine in early Parkinson\u2019s disease: a double blind controlled trial","volume":"49","author":"Dupont","year":"1986","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib628","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00313773","article-title":"Adjuvant treatment of Parkinson\u2019s disease with dopamine agonists: open trial with bromocriptine and CU 32-085","volume":"227","author":"Jellinger","year":"1982","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib629","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000115992","article-title":"Efficacy of pergolide and mesulergine","volume":"25","author":"Lieberman","year":"1986","journal-title":"Eur Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib630","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/sj.bjp.0702350","article-title":"Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist","volume":"126","author":"Reavill","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib631","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0028-3908(94)00146-J","article-title":"Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice","volume":"34","author":"Silva","year":"1995","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib632","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib633","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0091-3057(95)02280-5","article-title":"Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements","volume":"54","author":"Chesler","year":"1996","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib634","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s002130050322","article-title":"Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function","volume":"132","author":"Trevitt","year":"1997","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib635","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-002-1247-3","article-title":"Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor","volume":"165","author":"Carlson","year":"2003","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib636","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mds.870100111","article-title":"The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson\u2019s disease","volume":"10","author":"Neira","year":"1995","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib637","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1007\/s12035-022-03034-8","article-title":"Inhibition of spinal 5-HT3 receptor and spinal dorsal horn neuronal excitability alleviates hyperalgesia in a rat model of Parkinson\u2019s disease","volume":"59","author":"Li","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"8844","key":"10.1016\/j.pharmr.2025.100071_bib638","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","article-title":"Ondansetron for hallucinosis in advanced Parkinson\u2019s disease","volume":"341","author":"Zoldan","year":"1993","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib639","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib640","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/mds.870080315","article-title":"Cisapride treatment of constipation in Parkinson\u2019s disease","volume":"8","author":"Jost","year":"1993","journal-title":"Mov Disord"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100071_bib641","first-page":"673","article-title":"The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson\u2019s disease","volume":"106","author":"Jost","year":"1994","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib642","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/mds.870120324","article-title":"Long-term results with cisapride in Parkinson\u2019s disease","volume":"12","author":"Jost","year":"1997","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib643","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.parkreldis.2005.06.007","article-title":"Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson\u2019s disease","volume":"11","author":"Asai","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib644","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/mds.20387","article-title":"Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients","volume":"20","author":"Liu","year":"2005","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib645","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.WNF.0000240942.21499.97","article-title":"Tegaserod in constipation associated with Parkinson disease","volume":"30","author":"Morgan","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib646","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.20666","article-title":"Tegaserod (Zelnorm) for the treatment of constipation in Parkinson\u2019s disease","volume":"21","author":"Sullivan","year":"2006","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib647","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib648","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002826-200307000-00005","article-title":"Mirtazapine in L-Dopa-induced dyskinesias","volume":"26","author":"Meco","year":"2003","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib649","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib650","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.parkreldis.2015.05.016","article-title":"Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson\u2019s disease are associated with nonmotor symptoms","volume":"21","author":"Tong","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmr.2025.100071_bib651","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105314","article-title":"Reduced platelet 5-HT content is associated with rest tremor in Parkinson\u2019s disease","volume":"108","author":"Wang","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib652","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1192\/bjp.167.3.410b","article-title":"Brain damage and tardive dyskinesia","volume":"167","author":"Al-Adwani","year":"1995","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib653","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hup.470070109","article-title":"A case of Parkinson\u2019s disease exacerbated by fluoxetine","volume":"7","author":"Chouinard","year":"1992","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib654","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/jpet.102.039743","article-title":"Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates","volume":"303","author":"Hansard","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1_part_1","key":"10.1016\/j.pharmr.2025.100071_bib655","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.43.1_Part_1.211","article-title":"Increase of Parkinson disability after fluoxetine medication","volume":"43","author":"Jansen Steur","year":"1993","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib656","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.44.12.2406","article-title":"Parkinsonism exacerbated by paroxetine","volume":"44","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib657","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1531-8257(199901)14:1<155::AID-MDS1026>3.0.CO;2-Z","article-title":"Do serotonin reuptake inhibitor antidepressants worsen Parkinson\u2019s disease? A retrospective case series","volume":"14","author":"Richard","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmr.2025.100071_bib658","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pnpbp.2013.06.016","article-title":"5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms","volume":"46","author":"Shimizu","year":"2013","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib659","first-page":"332","article-title":"[Parkinsonism following addition of fluoxetine to the treatment with neuroleptics or carbamazepine]","volume":"136","author":"Touw","year":"1992","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib660","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00228-006-0233-9","article-title":"Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients","volume":"63","author":"Arbouw","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib661","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"issue":"S3","key":"10.1016\/j.pharmr.2025.100071_bib662","doi-asserted-by":"crossref","DOI":"10.1002\/mds.23884","article-title":"The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib663","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1163\/1569391041501924","article-title":"Antiparkinsonian actions of a selective 5-HT1A agonist, tandospirone, in rats","volume":"18","author":"Ishibashi","year":"2004","journal-title":"Biog Amines"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib664","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brainres.2006.07.003","article-title":"Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions","volume":"1112","author":"Matsubara","year":"2006","journal-title":"Brain Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib665","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.pnpbp.2010.04.005","article-title":"Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders","volume":"34","author":"Shimizu","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmr.2025.100071_bib666","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107997","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","volume":"167","author":"Fisher","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib667","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.35.1.83","article-title":"Initial treatment of parkinsonism with 8-alpha-amino-ergoline","volume":"35","author":"Ter\u00e4v\u00e4inen","year":"1985","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib668","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF00314036","article-title":"Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism","volume":"232","author":"Schneider","year":"1985","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib669","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00002826-198604000-00005","article-title":"Mesulergine (CU 32\u2013085) in the treatment of Parkinson\u02bcs disease","volume":"9","author":"Rascol","year":"1986","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib670","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00002826-199502000-00010","article-title":"Aggravation of parkinsonian tremor by cisapride","volume":"18","author":"Sempere","year":"1995","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib671","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/mds.28020","article-title":"A phase 2a trial investigating the safety and tolerability of the novel cortical enhancer IRL752 in Parkinson\u2019s disease dementia","volume":"35","author":"Svenningsson","year":"2020","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib672","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1523\/JNEUROSCI.07-02-00369.1987","article-title":"Ionic dependence of glutamate neurotoxicity","volume":"7","author":"Choi","year":"1987","journal-title":"J Neurosci"},{"issue":"8840","key":"10.1016\/j.pharmr.2025.100071_bib673","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0140-6736(93)92615-Z","article-title":"Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA\/kainate receptors","volume":"341","author":"Couratier","year":"1993","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib674","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1749-6632.1989.tb12502.x","article-title":"Neuronal Ca2+ channels and their regulation by excitatory amino acids","volume":"568","author":"Miller","year":"1989","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib675","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/0896-6273(89)90043-3","article-title":"Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress","volume":"2","author":"Murphy","year":"1989","journal-title":"Neuron"},{"issue":"S2","key":"10.1016\/j.pharmr.2025.100071_bib676","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF03160574","article-title":"Glutamate, excitotoxicity and amyotrophic lateral sclerosis","volume":"244","author":"Shaw","year":"1997","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib677","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/00001756-199504190-00030","article-title":"In vitro kainate injury to large, SMI-32(+) spinal neurons is Ca2+ dependent","volume":"6","author":"Carriedo","year":"1995","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib678","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00005072-199602000-00010","article-title":"Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis","volume":"55","author":"Ikonomidou","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib679","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2990.1993.tb00443.x","article-title":"Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease","volume":"19","author":"Ince","year":"1993","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100071_bib680","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1073\/pnas.90.14.6591","article-title":"Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity","volume":"90","author":"Rothstein","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5918","key":"10.1016\/j.pharmr.2025.100071_bib681","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.1166066","article-title":"Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis","volume":"323","author":"Kwiatkowski","year":"2009","journal-title":"Science"},{"issue":"Pt 7","key":"10.1016\/j.pharmr.2025.100071_bib682","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/brain\/awu120","article-title":"Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions","volume":"137","author":"Cooper-Knock","year":"2014","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib683","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nn.3230","article-title":"Divergent roles of ALS-linked proteins FUS\/TLS and TDP-43 intersect in processing long pre-mRNAs","volume":"15","author":"Lagier-Tourenne","year":"2012","journal-title":"Nat Neurosci"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100071_bib684","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/hmg\/ddx170","article-title":"The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis","volume":"26","author":"Farg","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib685","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13024-020-00386-4","article-title":"Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations","volume":"15","author":"Konopka","year":"2020","journal-title":"Mol Neurodegener"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib686","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1073\/pnas.1818415116","article-title":"Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects","volume":"116","author":"Mitra","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib687","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1038\/s41467-018-06111-6","article-title":"Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in Amyotrophic lateral sclerosis","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib688","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41593-017-0047-3","article-title":"TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS\/FTD","volume":"21","author":"Chou","year":"2018","journal-title":"Nat Neurosci"},{"issue":"7567","key":"10.1016\/j.pharmr.2025.100071_bib689","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature14974","article-title":"GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport","volume":"525","author":"Freibaum","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib690","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/nn.4085","article-title":"Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD\/ALS","volume":"18","author":"Jovi\u010di\u0107","year":"2015","journal-title":"Nat Neurosci"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib691","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1016\/j.celrep.2020.02.078","article-title":"Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes","volume":"30","author":"Sleigh","year":"2020","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib692","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41593-019-0397-0","article-title":"C9ORF72-ALS\/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo","volume":"22","author":"Choi","year":"2019","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib693","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1038\/s41598-017-06953-y","article-title":"TDP-43 stabilises the processing intermediates of mitochondrial transcripts","volume":"7","author":"Izumikawa","year":"2017","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100071_bib694","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1093\/hmg\/ddp421","article-title":"Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities","volume":"18","author":"Magran\u00e9","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100071_bib695","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.3390\/ijms21207525","article-title":"ALS-Related Mutant SOD1 Aggregates interfere with mitophagy by sequestering the autophagy receptor optineurin","volume":"21","author":"Tak","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib696","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40478-016-0301-z","article-title":"Pathological tau deposition in motor neurone disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy","volume":"4","author":"Behrouzi","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib697","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00401-003-0790-2","article-title":"Alpha-synuclein in motor neuron disease: an immunohistologic study","volume":"107","author":"Doherty","year":"2004","journal-title":"Acta Neuropathologica"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib698","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1038\/ncomms6845","article-title":"An acetylation switch controls TDP-43 function and aggregation propensity","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib699","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1471-4159.2009.06383.x","article-title":"TDP-43 is recruited to stress granules in conditions of oxidative insult","volume":"111","author":"Colombrita","year":"2009","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib700","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1074\/jbc.M117.814111","article-title":"Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration","volume":"293","author":"Goh","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100071_bib701","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fnmol.2017.00263","article-title":"Autophagy dysregulation in ALS: when protein aggregates get out of hand","volume":"10","author":"Ramesh","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.pharmr.2025.100071_bib702","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.598517","article-title":"Stress granule dysregulation in amyotrophic lateral sclerosis","volume":"14","author":"Dudman","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"43","key":"10.1016\/j.pharmr.2025.100071_bib703","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1073\/pnas.0607423103","article-title":"Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis","volume":"103","author":"Beers","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib704","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nn1885","article-title":"Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model","volume":"10","author":"Di Giorgio","year":"2007","journal-title":"Nat Neurosci"},{"issue":"42","key":"10.1016\/j.pharmr.2025.100071_bib705","doi-asserted-by":"crossref","first-page":"E6496","DOI":"10.1073\/pnas.1607496113","article-title":"Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism","volume":"113","author":"Ferraiuolo","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib706","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.neuron.2014.01.013","article-title":"Microglia induce motor neuron death via the classical NF-\u03baB pathway in amyotrophic lateral sclerosis","volume":"81","author":"Frakes","year":"2014","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib707","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nbt.1957","article-title":"Astrocytes from familial and sporadic ALS patients are toxic to motor neurons","volume":"29","author":"Haidet-Phillips","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib708","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nn1876","article-title":"Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons","volume":"10","author":"Nagai","year":"2007","journal-title":"Nat Neurosci"},{"issue":"7770","key":"10.1016\/j.pharmr.2025.100071_bib709","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1443-5","article-title":"Potential roles of gut microbiome and metabolites in modulating ALS in mice","volume":"572","author":"Blacher","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013346","article-title":"Platelet serotonin level predicts survival in amyotrophic lateral sclerosis","volume":"5","author":"Dupuis","year":"2010","journal-title":"PLOS ONE"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib711","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jnnp.42.7.640","article-title":"Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases","volume":"42","author":"Monaco","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib712","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02260888","article-title":"Biogenic amines and metabolites in spinal cord of patients with Parkinson\u2019s disease and amyotrophic lateral sclerosis","volume":"3","author":"Sofic","year":"1991","journal-title":"J Neural Transm Gen Sect"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100071_bib713","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0006-8993(91)91680-Y","article-title":"Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord","volume":"566","author":"Bertel","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100071_bib714","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-510X(96)00109-8","article-title":"Serotonergic neurotransmission in the spinal cord and motor cortex of patients with motor neuron disease and controls: quantitative autoradiography for 5-HT1a and 5-HT2 receptors","volume":"139 Suppl","author":"Forrest","year":"1996","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib715","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0001-22.2022","article-title":"Distribution features and potential effects of serotonin in the cerebrum of SOD1 G93A transgenic mice","volume":"9","author":"He","year":"2022","journal-title":"eNeuro"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib716","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/ijms21031107","article-title":"Implication of 5-HT in the dysregulation of chloride homeostasis in prenatal spinal motoneurons from the G93A mouse model of amyotrophic lateral sclerosis","volume":"21","author":"Martin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100071_bib717","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s10571-023-01320-0","article-title":"The serotonergic system and amyotrophic lateral sclerosis: a review of current evidence","volume":"43","author":"Yang","year":"2023","journal-title":"Cell Mol Neurobiol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib718","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/brain\/aww004","article-title":"Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis","volume":"139","author":"Vercruysse","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.pharmr.2025.100071_bib719","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.015960","article-title":"Global proteomics of Ubqln2-based murine models of ALS","volume":"296","author":"Whiteley","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100071_bib720","series-title":"Amine Oxidases: Function and Dysfunction","first-page":"253","article-title":"Reactive gliosis and monoamine oxidase B","author":"Ekblom","year":"1994"},{"key":"10.1016\/j.pharmr.2025.100071_bib721","series-title":"Amine Oxidases: Function and Dysfunction","first-page":"243","article-title":"Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography","author":"Jossan","year":"1994"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib722","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.clinph.2009.08.009","article-title":"Motoneuron excitability: the importance of neuromodulatory inputs","volume":"120","author":"Heckman","year":"2009","journal-title":"Clin Neurophysiol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib723","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.0000000000000806","article-title":"Medullary serotonergic system: organization, effects, and clinical correlations","volume":"83","author":"Benarroch","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib724","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/157015906776359540","article-title":"Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology","volume":"4","author":"Ciranna","year":"2006","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib725","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1254\/jjp.84.467","article-title":"The effects of melatonin in glutamate-induced neurotoxicity of rat cerebellar granular cell culture","volume":"84","author":"Gepdiremen","year":"2000","journal-title":"Jpn J Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib726","first-page":"829","article-title":"Antagonistic effects of melatonin on glutamate release and neurotoxicity in cerebral cortex","volume":"20","author":"Zhang","year":"1999","journal-title":"Zhongguo Yao Li Xue Bao"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib727","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.38.9.1464","article-title":"Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis","volume":"38","author":"Manaker","year":"1988","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib728","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/brain\/awh428","article-title":"[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS","volume":"128","author":"Turner","year":"2005","journal-title":"Brain"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100071_bib729","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/01.wnl.0000259083.31837.64","article-title":"Cortical 5-HT1A receptor binding in patients with homozygous D90A SOD1 vs sporadic ALS","volume":"68","author":"Turner","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pharmr.2025.100071_bib730","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2020.103471","article-title":"5-HT2A\/B receptor expression in the phrenic motor nucleus in a rat model of ALS (SOD1G93A)","volume":"279","author":"Borkowski","year":"2020","journal-title":"Respir Physiol Neurobiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib731","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-016-1534-4","article-title":"Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis","volume":"131","author":"El Oussini","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib732","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.25030","article-title":"Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis","volume":"82","author":"El Oussini","year":"2017","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib733","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1172\/JCI70338","article-title":"Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis","volume":"123","author":"Berglund","year":"2013","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib734","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1152\/jn.00774.2010","article-title":"Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity","volume":"105","author":"Murray","year":"2011","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.pharmr.2025.100071_bib735","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.nbd.2013.02.011","article-title":"Embryonic alteration of motoneuronal morphology induces hyperexcitability in the mouse model of amyotrophic lateral sclerosis","volume":"54","author":"Martin","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmr.2025.100071_bib736","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701550","article-title":"Genetic analysis of tryptophan metabolism genes in sporadic amyotrophic lateral sclerosis","volume":"12","author":"Fifita","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib737","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib738","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurol"},{"issue":"9013","key":"10.1016\/j.pharmr.2025.100071_bib739","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib740","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2012","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib741","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3164\/jcbn.17-62","article-title":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?","volume":"62","author":"Watanabe","year":"2018","journal-title":"J Clin Biochem Nutr"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib742","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7-8","key":"10.1016\/j.pharmr.2025.100071_bib743","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.pharmr.2025.100071_bib744","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101590","article-title":"Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis","volume":"52","author":"Brooks","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib745","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mus.27946","article-title":"The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis","volume":"68","author":"Brooks","year":"2023","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib746","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis","volume":"267","author":"Lunetta","year":"2020","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib747","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel","year":"2022","journal-title":"JAMA Neurol"},{"issue":"sup1","key":"10.1016\/j.pharmr.2025.100071_bib748","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21678421.2017.1362000","article-title":"Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib749","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1021\/bi026979d","article-title":"Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria","volume":"42","author":"Rodrigues","year":"2003","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib750","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03077.x","article-title":"Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice","volume":"93","author":"Ryu","year":"2005","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib751","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate\u2013taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib752","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/jnnp-2022-329024","article-title":"Effect of sodium phenylbutyrate\/taurursodiol on tracheostomy\/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial","volume":"93","author":"Paganoni","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib753","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100071_bib754","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100071_bib755","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/BF00370302","article-title":"Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre","volume":"419","author":"Benoit","year":"1991","journal-title":"Pflugers Arch"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib756","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0304-3940(94)90053-1","article-title":"Neuroprotective effects of riluzole on N-methyl-d-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices","volume":"177","author":"Malgouris","year":"1994","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib757","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/14660820310009389","article-title":"The serotonin precursor 5-hydroxytryptophan delays neuromuscular disease in murine familial amyotrophic lateral sclerosis","volume":"4","author":"Turner","year":"2003","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib758","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1152\/jn.00425.2013","article-title":"Effect of fluoxetine on disease progression in a mouse model of ALS","volume":"111","author":"Koschnitzky","year":"2014","journal-title":"J Neurophysiol"},{"issue":"5-6","key":"10.1016\/j.pharmr.2025.100071_bib759","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/21678421.2015.1026826","article-title":"A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: possible mitochondrial biomarker target engagement","volume":"16","author":"Macchi","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.pharmr.2025.100071_bib760","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16204","article-title":"In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis","volume":"31","author":"Schuster","year":"2024","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib761","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/mus.26335","article-title":"Rasagiline for amyotrophic lateral sclerosis: a randomized, controlled trial","volume":"59","author":"Statland","year":"2019","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib762","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s00415-004-0481-5","article-title":"Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model","volume":"251","author":"Waibel","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmr.2025.100071_bib763","first-page":"237","article-title":"Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis","volume":"41","author":"Jossan","year":"1994","journal-title":"J Neural Transm Suppl"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib764","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00863772","article-title":"An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis","volume":"241","author":"Mazzini","year":"1994","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib765","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jnr.490310223","article-title":"Deprenyl reduces the death of motoneurons caused by axotomy","volume":"31","author":"Salo","year":"1992","journal-title":"J Neurosci Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib766","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/14660820410017037","article-title":"(-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients","volume":"5","author":"Shahani","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib767","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.bjp.0701885","article-title":"The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the PMN mouse","volume":"124","author":"Duong","year":"1998","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100071_bib768","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjp.0702910","article-title":"Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons","volume":"128","author":"Duong","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib769","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.bjp.0702545","article-title":"Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex","volume":"127","author":"Labie","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib770","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100071_bib771","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.neuropharm.2005.07.006","article-title":"Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment","volume":"49","author":"Mart\u00ednez-Turrillas","year":"2005","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib772","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1043661802002050","article-title":"The activation of serotonin receptors prevents glutamate-induced neurotoxicity and NMDA-stimulated cGMP accumulation in primary cortical cell cultures","volume":"46","author":"Gandolfi","year":"2002","journal-title":"Pharmacol Res"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100071_bib773","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1113\/JP282509","article-title":"Serotonin 5-HT1A and 5-HT1B receptor-mediated inhibition of glutamatergic transmission onto rat basal forebrain cholinergic neurones","volume":"600","author":"Nishijo","year":"2022","journal-title":"J Physiol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100071_bib774","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.biopsych.2012.06.008","article-title":"Activation of 5-HT7 Serotonin Receptors Reverses Metabotropic Glutamate Receptor-Mediated Synaptic Plasticity in Wild-Type and Fmr1 Knockout Mice, a Model of Fragile X Syndrome","volume":"72","author":"Costa","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib775","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jnc.12157","article-title":"5-Hydroxytryptamine type 7 receptor neuroprotection against NMDA-induced excitotoxicity is PDGF\u03b2 receptor dependent","volume":"125","author":"Vasefi","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmr.2025.100071_bib776","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ntt.2019.01.002","article-title":"Protective effect of 5-HT7 receptor activation against glutamate-induced neurotoxicity in human neuroblastoma SH-SY5Y cells via antioxidative and antiapoptotic pathways","volume":"72","author":"Yuksel","year":"2019","journal-title":"Neurotoxicol Teratol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib777","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00314166","article-title":"Quantitative assessment of the effect of cyproheptadine on spastic paretic gait: a preliminary study","volume":"233","author":"Wainberg","year":"1986","journal-title":"J Neurol"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100071_bib778","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1523\/JNEUROSCI.3680-16.2017","article-title":"Mechanisms of enhanced phrenic long-term facilitation in SOD1G93A rats","volume":"37","author":"Nichols","year":"2017","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmr.2025.100071_bib779","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neuroscience.2013.06.068","article-title":"Spinal 5-HT7 receptors and protein kinase A constrain intermittent hypoxia-induced phrenic long-term facilitation","volume":"250","author":"Hoffman","year":"2013","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib780","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI93362","article-title":"The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C","volume":"127","author":"Lord","year":"2017","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib781","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0194599819846109","article-title":"Mice lacking brain-derived serotonin have altered swallowing function","volume":"161","author":"Haney","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib782","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/glia.22772","article-title":"Serotonin stimulates secretion of exosomes from microglia cells","volume":"63","author":"Glebov","year":"2015","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100071_bib783","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/glia.23933","article-title":"Serotonin receptor 4 regulates hippocampal astrocyte morphology and function","volume":"69","author":"M\u00fcller","year":"2021","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib784","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/17482968.2010.536839","article-title":"Depression in amyotrophic lateral sclerosis","volume":"12","author":"Atassi","year":"2011","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.pharmr.2025.100071_bib785","author":"Lynch"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib786","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archneur.55.1.93","article-title":"Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis","volume":"55","author":"Lange","year":"1998","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib787","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.bbi.2011.12.002","article-title":"Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity","volume":"26","author":"Krabbe","year":"2012","journal-title":"Brain Behav Immun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib788","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02900-0","article-title":"Evaluation of a 5-HT2B receptor agonist in a murine model of amyotrophic lateral sclerosis","volume":"11","author":"Arnoux","year":"2021","journal-title":"Sci Rep"},{"issue":"30","key":"10.1016\/j.pharmr.2025.100071_bib789","doi-asserted-by":"crossref","first-page":"11159","DOI":"10.1073\/pnas.0402026101","article-title":"Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model","volume":"101","author":"Dupuis","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib790","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1038\/s41467-020-17514-9","article-title":"Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model","volume":"11","author":"Guttenplan","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100071_bib791","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nn2047","article-title":"Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis","volume":"11","author":"Yamanaka","year":"2008","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmr.2025.100071_bib792","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112750","article-title":"Impact of 5-HT7 receptor inverse agonism of lurasidone on monoaminergic tripartite synaptic transmission and pathophysiology of lower risk of weight gain","volume":"148","author":"Fukuyama","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100071_bib793","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810013","article-title":"Distinct effects of escitalopram and vortioxetine on astroglial L-glutamate release associated with connexin43","volume":"22","author":"Shiroyama","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100071_bib794","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuropharm.2017.04.024","article-title":"Stimulation of the brain serotonin receptor 7 rescues mitochondrial dysfunction in female mice from two models of Rett syndrome","volume":"121","author":"Valenti","year":"2017","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100071_bib795","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.celrep.2017.05.023","article-title":"Synaptic remodeling depends on signaling between serotonin receptors and the extracellular matrix","volume":"19","author":"Bijata","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.pharmr.2025.100071_bib796","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neuropharm.2012.10.026","article-title":"The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways","volume":"67","author":"Speranza","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmr.2025.100071_bib797","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnbeh.2015.00062","article-title":"Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics","volume":"9","author":"Speranza","year":"2015","journal-title":"Front Behav Neurosci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100071_bib798","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/jnc.13962","article-title":"Serotonin 5-HT7 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons","volume":"141","author":"Speranza","year":"2017","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100071_bib799","doi-asserted-by":"crossref","first-page":"255","DOI":"10.31083\/j.fbl2810255","article-title":"Secondary protein aggregates in neurodegenerative diseases: almost the rule rather than the exception","volume":"28","author":"Moda","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100071_bib800","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-9-43","article-title":"Alpha-synuclein and tau: teammates in neurodegeneration?","volume":"9","author":"Moussaud","year":"2014","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100071_bib801","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-022-02524-2","article-title":"LATE-NC staging in routine neuropathologic diagnosis: an update","volume":"145","author":"Nelson","year":"2023","journal-title":"Acta Neuropathol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:09:57Z","timestamp":1760551797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725074794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":794,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0031699725074794"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100071","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the serotonergic system in the treatment of neurodegenerative diseases\u2014emerging therapies and unmet challenges","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100071"}}